Summary
Ovarian aging, marked by follicle depletion and oocyte quality decline, involves complex metabolic alterations. This review synthesizes evidence that dysregulated metabolic reprogramming, encompassing energy, lipid, and nutrient metabolism, drives ovarian functional decline. Central to this process is a self-reinforcing “metabolism-epigenetics-immunity” triangular network, where mitochondrial dysfunction and NAD+ depletion disrupt epigenetic regulation and activate chronic inflammation, collectively accelerating follicular atresia and hormonal dysfunction. By integrating this mechanistic framework, we highlight emerging intervention strategies targeting metabolic hubs, such as mitochondrial rescue and senescent cell clearance, which offer new avenues for preserving ovarian function. This work provides a conceptual foundation for developing personalized strategies to mitigate reproductive aging and its systemic health impacts.
Subject areas: human metabolism, epigenetics, immunity
Human metabolism; epigenetics; immunity
Introduction
Clinical phenotypes of ovarian aging and their metabolic basis
Ovarian aging is a core event in the functional decline of the female reproductive system, characterized by the irreversible depletion of the follicle pool and progressive deterioration of oocyte quality.1 This process encompasses the age-related nonlinear physiological decline in ovarian function,2 as well as pathological phenotypes such as premature ovarian failure (POF), premature ovarian insufficiency (POI), and diminished ovarian reserve (DOR).3 Epidemiological studies highlight its substantial disease burden: a 2024 evidence-based guideline indicates that the prevalence of non-iatrogenic POI has increased from approximately 1% to 3.5%–3.7%.4 Additionally, an analysis of 612,390 women aged 40–49 years across 55 low- and middle-income countries between 1990 and 2021 showed that the global prevalence of early menopause (40–44 years) reaches 15.8%, and that of premature menopause (before 40 years) reaches 4.9%.5 Clinical manifestations include menstrual irregularities and perimenopausal syndrome, which ultimately lead to infertility.6 Furthermore, estrogen deficiency associated with ovarian aging increases the long-term risk of conditions such as osteoporosis and cardiovascular diseases, thereby affecting women’s overall health and lifespan.7 Traditional aging theories have revealed important mechanisms underlying ovarian aging at multiple levels, including genetic inheritance,8 cell death,9 telomere shortening, and oxidative stress.10 However, the dynamic characteristics of ovarian function—such as nonlinearity and accelerated degeneration—suggest the existence of a more complex regulatory network. Evolutionary medicine research reveals that accelerated ovarian aging in modern society is closely associated with developmental programming disorders and evolutionary mismatch (the conflict between extended lifespan and conserved age at menopause).11 Specifically, developmental programming disorders are typically triggered by an adverse intrauterine environment (e.g., maternal malnutrition, stress, or environmental toxins) and may lead to accelerated ovarian aging in later life. This susceptibility primarily stems from impaired initial establishment of the primordial follicle pool during fetal development,12 deepening our understanding of the complexity of ovarian aging from the perspectives of life origin and evolutionary history. Of particular importance is that the irreversible depletion of the follicle pool serves as the core of ovarian function decline, and current intervention approaches still remain insufficient to achieve functional restoration.13
In this context, approaching from the perspective of energy metabolism provides a complementary and integrative framework for understanding this complex process. As the basic functional unit of the ovary, a follicle comprises a core oocyte and supporting cells,14 and its function is highly dependent on energy supply. The “high energy consumption” and “high dependency” characteristics mainly stem from the unique biological properties of the oocyte. As the largest cell in the mammalian body, its cytoplasm is rich in a large number of mitochondria, with a quantity exceeding that of other somatic cells.15 During development, the volume of a rapidly growing antral follicle can increase dozens of times, accompanied by the rapid proliferation of granulosa cells (GCs) and theca cells; studies have shown that the glucose uptake rate of a single follicle can be several times that of surrounding tissues, and the level of adenosine triphosphate (ATP) in follicular fluid is positively correlated with oocyte quality.16 Moreover, even primordial follicles in a quiescent state require their oocytes to maintain relatively high basal metabolic activity to ensure organelle homeostasis, with a basal oxygen consumption rate significantly higher than that of ordinary somatic cells.17 In addition, as an important endocrine organ, the ovary needs to consume a large amount of NADPH and ATP for the synthesis of steroid hormones such as estrogen; these reactions occur in mitochondria, further highlighting its energy-dependent nature. The oxygen consumption rate of unit ovarian tissue can reach a peak before ovulation, which is comparable to that of high-metabolism organs such as the liver and skeletal muscle.16,17 Therefore, the theory of metabolic reprogramming may provide a new molecular framework for understanding ovarian aging.
Core mechanisms of metabolic reprogramming in ovarian aging
Metabolic reprogramming is crucial for follicular development. Its unique energy metabolism pattern is established as early as the primordial germ cell (PGC) stage and regulates the reprogramming of PGCs into pluripotent stem cells.18 Thus, metabolic reprogramming is a continuous physiological process that runs through the entire cycle of follicular development, maturation, and degeneration, aimed at maintaining follicular metabolic homeostasis.19 As ovarian aging progresses, this homeostasis is disrupted, characterized by increased chromosomal abnormality rate in oocytes, mitochondrial dysfunction, impaired antioxidant capacity, and other phenomena—all of which are essentially associated with cellular metabolic disorders.20
In this process, mitochondrial dysfunction occupies a pivotal position, playing dual roles as an “initiating factor” and an “effector amplifier” that drives a self-reinforcing vicious cycle. Multiple aging-related factors can directly induce initial damage, manifested as mitochondrial DNA (mtDNA) mutations, electron transport chain abnormalities, and dysregulated quality control.15 As a key early driving event, the resulting reduction in oxidative phosphorylation (OXPHOS) efficiency triggers an energy crisis and reactive oxygen species (ROS) burst, which in turn initiates compensatory upregulation of glycolysis.21 However, this dysregulated reprogramming, along with the accompanying metabolite accumulation and nicotinamide adenine dinucleotide (NAD+) depletion, impairs the functions of oocytes and GCs, thereby accelerating follicular atresia. The resulting microenvironment of functional decline (such as chronic inflammation and exacerbated oxidative stress) in turn further exacerbates mitochondrial damage.
This mitochondria-centered metabolic imbalance further expands and intertwines with wider metabolic network dysregulation. For example, fatty acid metabolic rearrangement impairs cell membrane integrity and affects signal transduction;22 dysregulated amino acid metabolism disrupts protein homeostasis and epigenetic regulation;23 and the depletion of the key metabolic coenzyme NAD+ directly impairs energy metabolism, DNA repair, and inflammatory regulation capabilities, serving as a molecular hub that links various metabolic imbalances to functional decline.24
The aforementioned metabolic imbalances and ovarian function decline form a causal loop, indicating that dysregulated metabolic reprogramming is not only a driver of aging but also reflects the ultimate decompensation of the adaptive efforts by cells to maintain homeostasis. The nonlinear decline in ovarian function may be associated with the accumulation of metabolic damage exceeding the homeostatic threshold during the life cycle.25 This provides a theoretical framework for targeted interventions. This article focuses on how energy metabolism disorders, lipid disturbances, and nutritional sensing dysregulation drive follicular atresia and hormone synthesis failure, and explores novel intervention strategies targeting metabolic hubs, aiming to offer new directions for preserving oocyte quality and improving reproductive outcomes.
Types of metabolic reprogramming in ovarian aging
Energy metabolism disorders
Mitochondrial dysfunction
Mitochondrial dysfunction constitutes a core link in metabolic reprogramming during ovarian aging. Factors such as environmental toxins or oxidative stress can induce mtDNA mutations, impair the function of respiratory chain complexes, and are associated with reduced OXPHOS efficiency, decreased ATP synthesis, and excessive ROS production.26 Reduced OXPHOS efficiency triggers compensatory mechanisms, enhancing cellular dependence on the Warburg effect.27 Due to the limited self-repair capacity of oocytes, damage accumulates gradually, eventually leading to energy crisis, meiotic errors, and decreased embryonic developmental potential, thereby forming a vicious cycle of damage and metabolic imbalance.28 Mechanistically, the tumor suppressor HMG-box protein 1 (Hbp1) reduces ROS production by inhibiting the p53-p66Shc pathway and promotes the assembly of respiratory chain complex IV, making it a key regulator for maintaining the homeostasis of the primordial follicle pool. Deletion of Hbp1 results in decreased mitochondrial membrane potential of primordial follicles, premature follicular activation, and accelerated depletion of ovarian reserve—indicating that mitochondrial metabolic disorders are an important mechanism driving the decline of the follicle pool.29 Furthermore, in hypoxic regions of the aging ovary (e.g., atretic follicles), the hypoxic microenvironment induces mitochondrial protein lactylation. Lactic acid interferes with OXPHOS through oxygen consumption, leading to impaired function and dysregulated lactate metabolism—this constitutes a novel metabolic disorder mechanism independent of mtDNA mutations.30
Mitochondrial quality control is crucial for delaying ovarian aging. The endogenous factor stanniocalcin-1 serves as a key regulator of mitochondrial antioxidant defense, contributing to the maintenance of oocyte mitochondrial functional homeostasis.31 Pharmacological studies have demonstrated that coenzyme Q10 can reverse ATP synthesis defects and ROS accumulation in aged oocytes by enhancing the activity of respiratory chain complexes, indicating that restoring OXPHOS function plays an important role in preserving oocyte quality.32 Clinical studies have further revealed phenotypic differences in mitochondrial damage: patients with DOR and poor prognosis often exhibit mitochondrial dysfunction and simultaneous inhibition of both glycolytic and OXPHOS pathways, whereas age-related ovarian decline is mostly characterized by a compensatory shift from OXPHOS to glycolysis.33 In summary, mitochondrial dysfunction occupies a pivotal position in metabolic reprogramming during ovarian aging.
Pathological mechanisms of glycolytic compensation
Enhanced glycolysis serves as a compensatory response to mitochondrial dysfunction, characterized by an upregulated Warburg effect. This metabolic shift leads to the accumulation of intermediate products such as methylglyoxal (MGO), which directly impairs follicular function by inducing abnormal protein glycosylation. In oocytes of aged mice, the accumulation of high-mannose type N-glycans on membrane receptors blocks insulin signal transduction; in contrast, GCs of these mice exhibit a deficiency in core fucosylation modification, which reduces the activity of follicle-stimulating hormone (FSH) receptors.34 Clinical studies have confirmed that the glycolytic activity of GCs during the ovulatory phase is positively correlated with oocyte developmental competence. Aging and obesity disrupt this coupling, which is manifested as reduced lactate production by GCs and abnormal mitochondrial respiratory function.35 Metabolomic analyses have revealed the dynamic progression of this metabolic disorder. In GCs from patients with occult POI, a three-stage progressive failure pattern is exhibited, characterized by: early-stage reduction in glucose uptake mediated by glucose transporter 1 (GLUT1); mid-stage compensatory enhancement of glycolysis; and late-stage ATP depletion resulting from mitochondrial compensation failure.36 Aberrant glycolytic flux promotes the accumulation of MGO, triggering glycation stress and disrupting the SIRT1 functional network. This further inhibits the activity of the adenosine 5′-monophosphate-activated protein kinase (AMPK) pathway, leading to impaired autophagy, lipid droplet accumulation, and ultimately driving follicular atresia.37
In pathological follicular development disorders, impairment of nicotinamide phosphoribosyltransferase (NAMPT)-mediated NAD+ biosynthesis leads to decreased SIRT2 activity. This loss of SIRT2 function relieves the inhibitory effect on lactate dehydrogenase A (LDHA), driving GCs to form a high-lactate microenvironment. This microenvironment can induce histone lactylation modification, activate inflammatory responses, and disrupt the meiotic stability of oocytes.38 Furthermore, the chemical in vitro activation strategy can effectively promote the growth of primordial and secondary follicles in human ovarian tissue, and its effect is associated with the regulation of glycolysis and inflammation.39 In the hypoxic microenvironment, stabilized hypoxia-inducible factor 1 alpha transcriptionally activates glycolytic genes such as GLUT1 and LDHA. It also synergizes with the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome to enhance the Warburg effect, suggesting a synergistic interaction between glycolysis and inflammation.40 Notably, local ovarian metabolic abnormalities and systemic metabolic disorders (such as insulin resistance, obesity, and type 2 diabetes) exhibit a bidirectional association. Intraovarian insulin signaling impairment is not only a driver of aging, but the systemic metabolic dysregulation it induces can also increase the risk of related diseases; conversely, systemic insulin resistance can target and impair ovarian reserve, accelerating follicular depletion and forming a self-reinforcing vicious cycle.41 This indicates that the metabolic reprogramming in ovarian aging shares a pathophysiological basis with the widely occurring clinical metabolic disorders.
Lipid metabolism disorders
Fatty acid metabolic rearrangement and lipotoxic microenvironment
Ovarian aging is accompanied by significant fatty acid metabolic rearrangement, among which the dysfunction of peri-ovarian adipose tissue (POAT) serves as a key external factor in shaping the ovarian lipotoxic microenvironment. The postmenopausal decline in estrogen levels is closely associated with metabolic reprogramming of adipose tissue. Estrogen deficiency downregulates estrogen receptor alpha in adipose tissue, which relieves the inhibition of macrophage infiltration—this doubles the proportion of pro-inflammatory macrophages in POAT. Meanwhile, it activates hormone-sensitive lipase, promoting the release of free fatty acids (FFAs) and pro-inflammatory factors.42 FFAs and inflammatory factors derived from POAT infiltrate the ovarian stroma, driving lipid droplet accumulation, mitochondrial dysfunction, and local inflammation in GCs, thereby establishing a cascade of lipolysis and inflammation.43 Dysfunction of POAT also exacerbates local ovarian lipotoxicity and accelerates follicular atresia through the dysregulated secretion of adipokines such as adiponectin and leptin.44
There are also intrinsic defects within the ovary that contribute to lipid metabolism disorders. For instance, downregulation of the leptin receptor Ob-Rb leads to abnormal phosphorylation of Janus kinase (JAK)-2/STAT3, which inhibits autophagic flux, accelerates GC apoptosis, impairs follicular development, and disrupts the assembly of the meiotic spindle in oocytes.45 Defects in the LRRC4 gene induce mitochondrial fragmentation and fatty acid oxidation (FAO) impairment by disrupting the PERK-OPA1 signaling axis, accompanied by abnormal lipid droplet accumulation and reduced ATP synthesis—ultimately cutting off metabolic support for oocytes.46 Single-cell multi-omics studies further reveal that lipid metabolic reprogramming during oocyte maturation is closely associated with dysregulated GC-oocyte metabolic coupling. These studies have also identified key lipid homeostasis regulators such as carnitine palmitoyltransferase 1A and perilipin 2, whose dysregulated expression directly impairs embryonic developmental potential.47
Cholesterol imbalance and its effects
With advancing age, the decline in perimenopausal estrogen levels and systemic lipid metabolism disorders—such as reduced high-density lipoprotein (HDL) function and accumulation of oxidized low-density lipoprotein (LDL)—induce ovarian oxidative stress, inflammation, and local lipotoxicity, forming a key pathological link in ovarian aging.48 As a precursor for steroid hormone synthesis, changes in cholesterol levels and imbalance in the homeostasis of its intermediates can affect ovarian hormone production and reproductive function by inducing ferroptosis in GCs.49 Deletion of the vitamin D receptor impairs the synthesis and accumulation of 7-dehydrocholesterol (7-DHC, a cholesterol precursor with antioxidant and anti-aging effects) in the ovary, leading to damaged mitophagy, ROS accumulation, and GCs death. This directly establishes a causal relationship between cholesterol metabolism disorders and ovarian aging.50 Furthermore, multinucleated giant cells (MNGCs) accumulated in the aging ovary highly express lipid-degrading genes (e.g., LIPA) and are responsible for phagocytosing and degrading lipids released by atretic follicles. Impairment of their function results in lipid clearance disorders and mitophagy dysregulation, which in turn damage residual follicles, oocytes, and GCs, accelerating the decline of ovarian function.51 Studies have found that patients with POI often exhibit an atherogenic lipid profile similar to that of postmenopausal women (high triacylglycerol, low HDL, high small dense LDL). This confirms that ovarian failure is an important driver of systemic lipid metabolism disorders and suggests that the disrupted lipid microenvironment can exacerbate oxidative stress and lipotoxicity in residual ovarian tissue through the circulatory system.52 In addition, adipose tissue dysfunction can also impair ovarian function through non-lipotoxic pathways. For example, obesity induces excessive production of the local ovarian anti-inflammatory factor interleukin-10, which inhibits vascular endothelial growth factor signaling, disrupts the vascular network required for follicular development, and leads to folliculogenesis disorders.53 It is thus evident that cholesterol metabolism imbalance and the cascade reactions it triggers are involved in the pathophysiological process of ovarian aging.
Lipid peroxidation and ferroptosis
Ferroptosis is an iron-dependent form of programmed cell death driven by lipid peroxidation, and it plays a key role in accelerating follicular atresia. Studies have shown that, in oocytes of elderly women, the upregulated expression of acyl-coA synthetase long-chain family member 4 (ACSL4) and the decreased activity of glutathione (GSH) peroxidase 4 (GPX4) collectively promote the accumulation of lipid peroxidation. The application of the ferroptosis inhibitor liproxstatin-1 can effectively restore meiotic stability and improve embryonic developmental potential, providing key evidence for targeting the GPX4/ACSL4 axis to delay ovarian aging.54 Chemotherapeutic drugs such as alkylating agents and environmental toxins such as aflatoxin B1 can also activate lipid peroxidation and ferroptosis in oocytes by inducing oxidative stress, accelerating the depletion of the follicle pool.55,56 Dietary antioxidant deficiency is an important inducer of lipid peroxidation accumulation in oocytes. Large-scale cohort studies have shown that the total serum antioxidant capacity of patients with POI is lower than that of healthy controls, and the level of caffeic acid is positively correlated with anti-Müllerian hormone (AMH). Meanwhile, the level of malondialdehyde (MDA)—a terminal product of lipid peroxidation—in their follicular fluid is doubled; MDA can directly damage the function of mitochondrial complex I in oocytes, providing a molecular pathological basis for ovarian aging.57 In terms of regulatory mechanisms, the upregulated expression of GPX4 can inhibit lipid peroxidation and ferroptosis in GCs, further confirming the pathogenic role of this pathway in ovarian aging.58 AdipoRon, an adiponectin receptor agonist, can effectively block the ferroptosis cascade by inhibiting ACSL4-mediated polyunsaturated fatty acid (PUFA) phospholipid synthesis in GCs.59 In summary, lipid metabolic reprogramming activates the ferroptosis pathway by inducing membrane phospholipid peroxidation. Targeting the ACSL4/GPX4 axis has become a potential strategy for intervening in ovarian aging, providing an important theoretical framework for understanding the mechanism of follicular atresia.60
Nutritional metabolism disorders
Amino acid metabolism abnormalities
Ovarian aging is accompanied by significant amino acid metabolism disorders. Large-sample serum metabolomic studies have shown that the levels of essential amino acids such as branched-chain amino acid (BCAA) and tryptophan in the serum of patients with DOR are generally reduced.61 A decrease in leucine levels, impairment of signal sensing, or exposure to toxic substances with leucine-like structures can trigger endoplasmic reticulum stress and inhibit the activity of mammalian target of rapamycin complex 1 (mTORC1).62 This not only impairs protein synthesis—affecting the supplementation of oocyte reserve factors and the integrity of the meiotic apparatus—but also disrupts the regulation of autophagic flux, leading to impaired autophagosome clearance, accumulation of p62, and damage to mitochondrial function.63
To cope with energy stress or biosynthetic demands, amino acid catabolic pathways may be upregulated. In aged oocytes, glutamine metabolism is enhanced: it replenishes tricarboxylic acid (TCA) cycle intermediates by generating α-ketoglutarate (α-KG) and provides precursors for nucleotide synthesis.64 Dysregulation of key metabolites in the serine/glycine/one-carbon metabolism pathway (e.g., homocysteine accumulation) consumes the methyl donor S-adenosylmethionine, leading to hypermethylation of DNA/RNA and impairing the synthesis of antioxidants such as GSH.65 Oocytes rely on a large number of extremely long-lived proteins (e.g., zona pellucida proteins, spindle-associated proteins) to maintain their characteristics, making them particularly sensitive to protein homeostasis imbalance caused by amino acid metabolism disorders.66 If abnormal amino acid availability or metabolic stress impairs chaperones, the ubiquitin-proteasome pathway, and the autophagic clearance system, it will result in the accumulation of unfolded/misfolded proteins and toxic aggregates. This threatens the structure and function of key oocyte proteins, ultimately causing GCs dysfunction, increased meiotic error rates in oocytes, and accelerated depletion of ovarian reserve.67 In addition, changes in amino acid metabolism can also affect the synthesis of hormone precursors. For example, tryptophan serves as a precursor for serotonin; its metabolic disorders and downregulation of key synthetic enzymes (e.g., Tph1) impair GCs function and lead to hormonal imbalance.68
Nucleotide metabolism disorders
Nucleotide metabolism disorders, particularly the decline in the level of the key coenzyme NAD+, are critical factors contributing to impaired DNA repair during ovarian aging. NAD+ links nucleotide metabolism to energy production efficiency by driving ATP synthesis69; NAD+ precursors (e.g., nicotinamide mononucleotide, NMN) improve the quality of aged oocytes by activating SIRT proteins, which is essential for maintaining spindle stability and chromosome integrity. The depletion of NAD+ is a driver of oocyte aging.70 Meanwhile, ATP—a nucleotide derivative—serves as the core carrier of oocyte energy metabolism, and its level directly determines ovarian function.71 Mitochondrial dysfunction, which is prevalent in aged GCs, leads to a significant reduction in ATP production, increasing the difficulty of de novo nucleotide synthesis, salvage synthesis, and energy-intensive DNA repair.72
These metabolic abnormalities trigger cascading pathological effects: the deficiency of deoxyribonucleoside triphosphates (dNTPs) reduces the efficiency of homology-directed repair (HDR), and functional defects in key HDR factors (e.g., the MCM8/MCM9 complex) are closely associated with POF73; in the Chinese Hui population, single nucleotide polymorphisms in the MCM8 gene have been identified as potential genetic risk factors for POF.74 Furthermore, the level of 8-hydroxy-2′-deoxyguanosine (8-OHdG)—a marker of DNA oxidative damage—is significantly elevated in the aging ovary, and its accumulation is negatively correlated with the expression of nucleotide metabolism genes.75 This strongly confirms the pivotal role of the collapse of the “metabolism-genome stability axis” in the decline of ovarian function (Figure 1). A summary of the key molecular changes, cascade pathological effects, and pathological mechanisms of metabolic reprogramming in the three core metabolic disorders is presented in Table 1.
Figure 1.
Core types and pathological pathways of metabolic reprogramming in ovarian aging
This schematic delineates the three core types of metabolic dysregulation—energy, lipid, and nutritional metabolism disorders—and their interconnected pathological cascades that drive ovarian aging. The diagram illustrates how initial insults (e.g., mtDNA mutations, nutrient level alterations) trigger specific metabolic defects, which converge on critical cellular dysfunctions in both oocytes and granulosa cells. These dysfunctions, including bioenergetic crisis, lipotoxicity, oxidative stress, impaired protein translation, and compromised DNA repair, collectively lead to follicular atresia, diminished ovarian reserve, and the phenotypic manifestations of ovarian aging. Abbreviations are defined as follows: mtDNA, mitochondrial DNA; OXPHOS, oxidative phosphorylation; ATP, adenosine triphosphate; ROS, reactive oxygen species; MGO, methylglyoxal; GLUT1, glucose transporter 1; SCD1, stearoyl-coA desaturase 1; FFAs, free fatty acids; HDL, high-density lipoprotein; ox-LDL, oxidized low-density lipoprotein; ACSL4, acyl-coA synthetase long-chain family member 4; GPX4, glutathione peroxidase 4; BCAA, branched-chain amino acid; NAD+, nicotinamide adenine dinucleotide; SIRTs, sirtuins; POI, premature ovarian insufficiency; POF, premature ovarian failure; DOR, diminished ovarian reserve.
Table 1.
Molecular pathological alterations of metabolic reprogramming in ovarian aging
| Metabolic type | Metabolic imbalance | Molecules | Physiological functions | Pathological effects | Reference |
|---|---|---|---|---|---|
| Energy metabolism dysfunction | Mitochondrial dysfunction | mtDNA | Encode respiratory chain complexes | Mutations → respiratory chain deficiency and reduced ATP synthesis. | May-Panloup et al.26 |
| OXPHOS | Efficiently synthesize ATP | Decreased efficiency → elevated ROS → oocyte energy crisis. | May-Panloup et al.; Liu et al.; Zhang et al.26,27,28 | ||
| Hbp1 | Attenuates ROS; promotes CIV assembly | Deficiency → decreased mitochondrial membrane potential → premature follicular activation. | Dong et al.29 | ||
| Glycolytic compensation | MGO | Glycolytic intermediates | Accumulation → abnormal glycosylation → autophagy impairment → follicular atresia. | Wu et al.; Emidio et al.34,37 | |
| GLUT1 | Mediate glucose uptake | Decreased → reduced glucose uptake → impaired compensatory glycolysis → ATP depletion. | Marynowicz et al.36 | ||
| LDHA | Catalyze pyruvate → lactate | Upregulation → lactate-rich microenvironment → histone lactylation → meiotic defects. | Liu et al.; Yang et al.38,40 | ||
| Lipotoxic microenvironment | FFAs | Lipolysis products | Excess release → ovarian infiltration → lipotoxicity and local inflammation. | Leeners et al.; Dipali et al.42,43 | |
| Lipid droplet | Lipid storage/oxidative damage | Accumulation → mitochondrial dysfunction, local inflammation → follicular atresia. | Dipali et al.; Shang et al.43,46 | ||
| Leptin | Regulates metabolism and autophagy | Signaling disruption → inhibited autophagy → accelerated GC apoptosis and oocyte dysfunction. | Wołodko et al.45 | ||
| LRRC4 | Regulates mitochondrial dynamics and FAO via PERK-OPA1 | Defects → mitochondrial fragmentation, impaired FAO, lipid accumulation, and ATP deficiency. | Shang et al.46 | ||
| Cholesterol imbalance | 7-DHC | Cholesterol precursor, antioxidation | Abnormal → impaired mitophagy, ROS accumulation → GCs death. | Chen et al.50 | |
| Lipid peroxidation and ferroptosis | GPX4 | Suppresses lipid peroxidation | Inactivation → lipid peroxide accumulation → ferroptosis → follicle loss. | Zeng et al.; Tsui et al.54,58 | |
| ACSL4 | Activates PUFAs | Overexpression → increased PUFA phospholipids → enhanced lipid peroxidation → ferroptosis. | Zeng et al.; Zhou et al.54,59 | ||
| Nutritional metabolism dysregulation | Amino acid metabolism abnormality | BCAA | Regulate protein synthesis | Deficiency → impaired protein synthesis → ovarian aging. | Al Rashid et al.; Liu et al.; Zhang et al.61,62,63 |
| mTORC1 | Promotes anabolism | Inhibition → disrupted protein synthesis and autophagy → mitochondrial dysfunction. | Liu et al.; Zhang et al.62,63 | ||
| α-KG | TCA cycle anaplerosis and epigenetic cofactor | Reduced α-KG → ATP insufficient → inadequate energy supply to GCs/oocytes → cellular dysfunction, developmental arrest. | Zhang et al.76 | ||
| SAM | Methyl donor metabolism and antioxidant synthesis | Metabolites dysregulation → depletion of methyl donor SAM → DNA/RNA hypermethylation and impair antioxidant capacity. | Jia et al.65 | ||
| Tph1 | Synthesis of hormone precursors | Tryptophan metabolic disorder and downregulation of key synthetic enzymes → impairment of GCs function and hormonal imbalance. | Liu et al.68 | ||
| Nucleotide metabolism dysregulation | NAMPT | Rate-limiting enzyme in NAD+ biosynthesis | Impairment leads to decreased NAD+ levels, resulting in impaired DNA repair, reduced SIRT activity, and energy metabolism dysfunction. | Liu et al.38 | |
| NAD+ | DNA repair coenzyme, SIRT activator, energy metabolism hub | Decreased levels → impaired DNA repair; reduced efficiency of nucleotide metabolism and ATP generation. | Yaku et al.; Kordowitzki et al.69,70 | ||
| ATP | Core energy carriers | The level directly determines ovarian function | Wei et al.; Wen et al.71,72 | ||
| dNTPs | Raw materials for DNA synthesis and repair | Deficiency → decreased HDR efficiency → genomic instability. | Desai et al.; Ma et al.73,74 | ||
| 8-OHdG | Markers of DNA oxidative damage | Accumulation → negatively correlated with the expression of nucleotide metabolism. | Smits et al.75 |
Characteristics and regulatory networks of metabolic reprogramming in ovarian aging
Core characteristics and phenotypic markers of metabolic reprogramming
The interplay between glycolysis and SASP in a vicious cycle
The accumulation of senescent cells in the ovary is a key factor driving chronic inflammation. These cells are characterized by the release of the senescence-associated secretory phenotype (SASP)—a complex mixture containing various pro-inflammatory factors, chemokines, and proteases—which forms the basis of the local inflammatory microenvironment.77 Notably, there is a close and functional interaction between glycolysis and the SASP in senescent GCs. This association is not only reflected in the positive correlation between the expression level of hexokinase 2 (HK2), a key glycolytic enzyme, and the secretion of core SASP factors such as interleukin-6 (IL-6),78 but also supported by studies on upstream and downstream regulatory mechanisms. For example, in the CTX induced POI model, downregulated expression of SIRT1 can activate Foxo3a, thereby simultaneously upregulating the transcription of key glycolytic genes including HK2 and LDHA, and directly driving the release of SASP factors. This molecular pathway couples metabolic reprogramming with inflammatory output.79 More importantly, depletion of the core metabolic coenzyme NAD+ has been identified as a key upstream event driving the pro-inflammatory SASP program, which firmly couples cellular energy crisis with chronic inflammatory states at the fundamental level of energy sensing and allocation.80 Furthermore, other aging-related stresses can exacerbate this vicious cycle by activating the SASP.
Multi-omics studies have revealed that the transcriptional regulation of replicative senescence involves the synergistic action of TEA domain transcription factor 1 (TEAD1) and activator protein-1 (AP-1). The mammalian target of rapamycin (mTOR) signal directly drives SASP secretion by activating TEAD1; in contrast, ROS accumulation or metabolic stress activates the AP-1 complex. The AP-1 complex not only upregulates LDHA to promote metabolic reprogramming but also enhances the secretion of pro-inflammatory factors, collectively accelerating follicular dysfunction.81 The AP-1-mediated senescent transcriptional program is reversible: it establishes and maintains the sustained expression of pro-inflammatory genes by remodeling the enhancer landscape (e.g., acquiring H3K27 acetylation marks).82 The continuous accumulation of senescent cells relies on immune escape mechanisms, among which the p53-dependent hypusination modification of eukaryotic translation initiation factor 5A (eIF5A) is crucial. The loss of eIF5A impairs the translation efficiency of proteins such as mitochondrial respiratory chain complexes, leading to cellular energy metabolism disorders and ROS accumulation; meanwhile, it significantly reduces the expression of major histocompatibility complex class I (MHC-I) molecules, weakening the ability of CD8+ T cells to recognize and clear senescent cells. This loss of immune surveillance allows senescent cells to escape clearance and persist, further exacerbating SASP release and local inflammation.83 In summary, the accumulation of senescent cells, SASP-driven chronic inflammation, and their multi-level regulatory mechanisms collectively constitute an important pathological basis for ovarian aging.
Metabolic-epigenetic crosstalk
Metabolic reprogramming and epigenetic modifications exhibit tight, spatially specific, and multi-level crosstalk during oocyte aging. Studies have demonstrated that the maintenance of oocyte quality involves a functional interaction between DNA methylation and metabolism. For instance, changes in mtDNA methylation levels can affect the transcription of genes encoding respiratory chain complexes, inducing mitochondrial quiescence accompanied by lipid droplet accumulation, which in turn impacts oocyte maturation efficiency.84 At the nuclear genome level, demethylation of the promoter regions of antioxidant genes such as superoxide dismutase (SOD) and GPX can enhance the antioxidant capacity of GCs. This enables GCs to counteract oocyte quality decline caused by mitochondrial dysfunction and oxidative stress, with the nuclear receptor RORα playing a key mediating role in this pathway.85 In-depth studies have shown that the degradation of histone deacetylase 4 (HDAC4) during aging is a key event. The loss of HDAC4 relieves the inhibition of the AP-1/p300 transcriptional complex, leading to the enrichment of this complex in enhancer regions. This drives the high expression of pro-inflammatory factors, matrix remodeling enzymes (e.g., matrix metalloproteinases), and metabolic reprogramming genes, thereby shaping the core characteristics of the SASP.86 Furthermore, HDAC4 forms a complex with HDAC1/2 to specifically regulate histone H2B lysine 120 deacetylation; the loss of its function causes abnormal elevation of H2BK120ac, impairs the efficiency of HDR, and accelerates genomic instability and cellular senescence.87 In oocytes, alanyl-tRNA synthetase 2-mediated histone H3 lysine 18 lactylation maintains chromosome segregation by activating key meiotic genes such as Budding Uninhibited by benzimidazoles 1 and synaptonemal complex protein 3. The loss of this function results in reduced lactylation levels, meiotic errors, and accelerated follicular atresia, driving the development of POI.88 Long non-coding RNAs (lncRNAs) act as a bridge between epigenetic regulation and metabolic reprogramming. Studies have shown that specific lncRNAs can drive metabolism remodeling associated with cellular senescence by directly targeting metabolic enzymes or reshaping the epigenetic state of metabolic genes.89 For example, in ovarian GCs, the lncRNA ZNF674-AS1 specifically binds to aldolase, fructose-bisphosphate A (ALDOA)—a glycolytic enzyme. It reduces ALDOA activity by inhibiting the acetylation modification at its K230 site; meanwhile, it recruits HDAC4 to suppress ALDOA transcription. This dual effect leads to glycolytic disorders and proliferation defects, and this mechanism triggers an energy crisis in GCs in the ovarian tissue of patients with POI.90 Beyond classical epigenetic mechanisms, post-transcriptional modifications of maternal mRNA—such as N6-methyladenosine (m6A) methylation and uridylation—regulate mRNA stability and translation efficiency, thereby affecting protein synthesis. This process further couples core reprogramming events such as amino acid utilization and ATP metabolism.91 These studies reveal the complex coordinated regulatory mechanisms between epigenetic and metabolic networks during oocyte aging.
Regulatory molecules and pathways of metabolic reprogramming
Dysregulation of key signaling pathways
Nutrient-sensing pathways are generally dysregulated in ovarian aging and constitute core nodes of the regulatory network. Among them, the AMPK signal, as a core energy-sensing hub, regulates mTOR activity, autophagic processes, and FAO—all of which are directly associated with follicle survival. A recent study found that vitamin B12, a key cofactor in one-carbon metabolism, can influence the fate of cell proliferation or differentiation by regulating the RAS/MAPK signaling pathway.92 Epidermal growth factor (EGF) secreted by GCs, as an important paracrine signal, can enhance the activity of oocyte GSH synthetase and promote the transport of antioxidants; age-related downregulation of EGF signaling directly leads to the collapse of this metabolic support function.93 Specific metal ions (e.g., thallium, chromium trichloride, manganese dichloride, iron trichloride, zinc sulfate) can synergistically activate the glycolysis-mTOR pathway and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway. This activation upregulates key glycolytic proteins, such as glucose transporter 4, HK1, pyruvate kinase M2, and liver-type phosphofructokinase, thereby promoting follicle activation. These findings provide experimental evidence that metabolic pathways are precisely regulated by upstream signals.94 In contrast, targeted inhibition of the PI3K/Akt/mTOR pathway can improve the meiotic stability of oocytes by alleviating oxidative stress. This confirms the core role of excessive activation of this pathway in driving follicular dysfunction.95
Forkhead box protein O1 (FoxO1), a downstream effector of the PI3K/Akt pathway, maintains ovarian reserve by inhibiting excessive follicle activation. Defects in the CSE1L gene lead to abnormal accumulation of FoxO1 in the nucleus of GCs by disrupting nucleocytoplasmic transport; this accumulation further activates the expression of nuclear receptor coactivator 4 to drive ferroptosis, revealing the key role of FoxO1 in mediating GCs damage caused by iron metabolism disorders.96 Meanwhile, knockout of the FoxO3a gene causes premature depletion of primordial follicles in mice. This suggests that metabolic signals such as Akt (activated by insulin resistance) may induce nuclear export of FoxO3a through its phosphorylation, relieving the inhibition of follicle activation genes (e.g., Kit ligand) and ultimately accelerating ovarian aging.97 These signaling pathways profoundly affect the metabolic phenotype of cells by regulating the expression and activity of metabolic enzymes.
Core metabolic pathway disorders
NAD+ is a crucial metabolic coenzyme that not only participates in redox reactions but also serves as a substrate for deacetylases such as SIRTs.98 The NAD+/SIRT signaling pathway influences the cellular senescence process by regulating gene expression, DNA repair, cellular metabolism, and inflammatory responses.99 Studies have shown that the loss of key enzymes in the de novo NAD+ synthesis pathway can lead to a decrease in ovarian NAD+ levels, inhibit SIRT activity, and thereby accelerate follicle depletion, GCs dysfunction, and a decline in ovarian reserve—manifesting as an ovarian aging phenotype.100 Specifically, NAD+ depletion reduces the activity of mitochondrial antioxidant enzymes mediated by SIRT1/SIRT3; the accumulation of ROS triggers oxidative stress, hindering meiotic maturation and accelerating oocyte apoptosis.101 During the post-ovulatory oocyte aging process, the decreased activity of SIRT1 impairs its deacetylation capacity, leading to mitochondrial dysfunction, endoplasmic reticulum stress, and disrupted organelle crosstalk, which compromises the stability of the meiotic spindle.102 Notably, SIRT3 acts as a core factor maintaining ovarian mitochondrial metabolic homeostasis; its loss specifically impairs ovarian mitochondrial OXPHOS function and exacerbates mtDNA damage through an NAD+-dependent mechanism, ultimately resulting in POF.103 Collectively, these studies demonstrate that the attenuation of the NAD+/SIRT pathway and the subsequent impairment of mitochondrial function and DNA repair constitute an important foundation of the core metabolic disorder network in the process of ovarian aging (Figure 2).
Figure 2.
Dysregulation of key signaling pathways and core metabolic pathways in ovarian aging
This schematic illustrates the core pathological network driving ovarian functional decline, initiated by the imbalance of key nutrient-sensing pathways (PI3K-Akt and mTOR hyperactivation coupled with AMPK suppression), this convergence inhibits FoxO transcription factors. Attenuates the NAD+-SIRT axis, which collectively triggers ROS accumulation, genomic instability, and a chronic inflammatory state via the SASP. This self-reinforcing cycle of metabolic dysregulation, oxidative stress, and inflammation ultimately manifests as follicular over-activation and ovarian reserve depletion. Abbreviations are defined as follows: NAD+, nicotinamide adenine dinucleotide; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; NADH, nicotinamide adenine dinucleotide (reduced form); LDHA, lactate dehydrogenase A; SASP, senescence-associated secretory phenotype; MGO, methylglyoxal: GLUT1, glucose transporter type 1; HK, hexokinase; PKM2, pyruvate kinase M2; PFKL, liver-type phosphofructokinase; SOD, superoxide dismutase; CAT, catalase; GPx, glutathione peroxidase.
Metabolic coupling dysregulation in follicular units
There is precise metabolic coupling between GCs and oocytes within the follicle, which is crucial for maintaining oocyte quality. This is centrally reflected in the “metabolic sensor” function of the cumulus-oocyte complex (COC): oocytes rely on cumulus cells to provide key metabolic substrates such as pyruvate, hypoxanthine, and NADPH to maintain energy homeostasis and reducing power. In turn, cumulus cells receive signaling factors like GDF9/BMP15 secreted by oocytes through gap junctions, regulating their own glycolysis and cholesterol metabolism. Together, these processes determine oocyte developmental potential.104 Maintaining this coupling depends on multiple communication mechanisms. Connexin 43-mediated gap junction intercellular communication (GJIC) between GCs and oocytes is an important channel for direct exchange of metabolites and small-molecule signals. The decline in GJIC function, combined with abnormal signal transmission via extracellular vesicles (EVs), collectively leads to reduced metabolite transfer efficiency and failure of cellular stress responses.105 Exosomal microRNAs (ex-miRs) transmitted via EVs between COCs and surrounding GCs form an independent molecular axis regulating metabolic coupling. Specific ex-miRs directly regulate glycolysis, mitochondrial function, and apoptosis processes in GCs and oocytes by targeting pathways such as PI3K-Akt and TGF-β/SMAD. Dysregulated expression of these ex-miRs is a key link in the collapse of metabolic function in poor ovarian response.106 Metabolic coupling between GCs and oocytes also relies on paracrine signals. For example, Activins bind to activin type II receptors on the oocyte surface, activating the Smad2/3 signaling pathway and promoting the expression of GSH synthetase in GCs, thereby enhancing the transport capacity of antioxidants to oocytes.107
The physical and biochemical properties of the extracellular matrix (ECM) are key mechanical elements in the ovarian microenvironment, which directly regulate the metabolic state and function of GCs through mechanical signal transduction.108 During ovarian aging, pathological remodeling occurs in the ECM, including changes in stiffness, topological structure, and components. These altered ECM signals are mainly sensed by the integrin receptor family on the GCs surface,109 which in turn activates the downstream focal adhesion kinase (FAK). Although direct evidence is lacking in GCs, numerous studies have demonstrated that the integrin-FAK axis serves as a key bridge connecting cellular mechanosensing and metabolic reprogramming. Upon FAK activation, it can extensively regulate cellular energy metabolic programs by initiating downstream pro-survival and anabolic pathways such as PI3K/Akt, or by inhibiting energy sensors including AMPK. In cells such as glioma, it has been confirmed that integrin-FAK signaling can directly drive the reprogramming of glucose metabolism and glycolysis.110,111 Particularly critically, the mechanical properties of the ECM itself act as a powerful “switch” for metabolic regulation, which can directly instruct cells to adjust their energy metabolic pathways to adapt to microenvironmental changes.112 Based on this, we reasonably speculate that in aging ovaries, the stiff fibrotic ECM may force GCs into a metabolically dysfunctional state via aberrant integrin-FAK signaling, thereby exacerbating the dysregulation of metabolic coupling within the follicular unit. Furthermore, the dynamic coupling between bioelectrical signals and metabolic reprogramming also exerts precise regulation on the metabolic coupling between cumulus cells and oocytes; dysregulation at this level can directly disrupt energy allocation efficiency, ultimately affecting oocyte quality.113 Table 2 summarizes the characteristics of metabolic reprogramming in key cell types involved in ovarian aging and their functional impacts, revealing the core mechanism of intrafollicular metabolic coupling dysregulation.
Table 2.
Metabolic characteristics and aging-related changes of key ovarian cell types
| Cell type | Metabolic reprogramming in aging | Functional impact |
|---|---|---|
| Oocyte | mtDNA mutation → decreased OXPHOS efficiency → compensatory upregulation of glycolysis26,27,28; NAD+ depletion → decreased activity of SIRTs → mitochondrial dysfunction.70,101 |
Energy crisis; meiotic errors. |
| Granulosa cells | Enhanced glycolysis → accumulation of MGO → glycative stress34,37; NAD+ depletion → decreased SIRTs → increased LDHA → high-lactate microenvironment38; increased ACSL4/decreased GPX4 → ferroptosis54; dysregulation of amino acid metabolism → impaired autophagy.67 |
Collapse of metabolic support function; hormone synthesis dysfunction; acceleration of follicular atresia. |
| Ovarian stromal cells | FFAs increased release → increased proinflammatory factors → macrophage infiltration → lipotoxic microenvironment.42,43 | Increased local inflammation → deterioration of the follicular developmental microenvironment. |
| Senescent cells | Glycolysis and SASP (co-expression of HK2 upregulation and IL-6 upregulation)77,78; AP-1/TEAD1 → activation of proinflammatory genes81,82; NAD+ depletion → decreased SIRTs → increased histone acetylation → NF-κB activation.114 |
SASP secretion → activation of inflammatory genes → chronic inflammation; metabolic dysregulation → epigenetic modifications → immunity (NF-κB activation) forming a feedback loop. |
| Macrophages | Decreased estrogen → downregulation of estrogen receptor alpha in adipose tissue → relief of inhibition on macrophage infiltration.42,43 | Increased macrophage infiltration → proinflammatory microenvironment → lipolysis and inflammation → lipotoxic microenvironment |
| MNGCs | Highly express lipid-degrading genes (e.g., LIPA); impaired lipid clearance and mitophagy regulation.51 | Accumulation of lipids and damaged organelles → damage to residual follicles, oocytes, and GCs → accelerated decline of ovarian function. |
| Metabolic coupling units | COC form metabolic sensors; impaired GJIC function → decreased efficiency of metabolite transfer; dysregulation of ex-miRs → dysregulation of glycolysis/mitochondrial function; dysregulated paracrine signaling → attenuated antioxidant support105,106,107,113; pathological ECM remodeling (increased stiffness, fibrosis) → integrin-FAK mechanosensing → metabolic reprogramming of GCs.109,112 |
Disruption of energy allocation efficiency; meiotic errors; acceleration of follicular atresia; contributes to GCs metabolic dysfunction and exacerbates intrafollicular coupling dysregulation. |
Metabolic-immune-epigenetic crosstalk network
During the process of ovarian aging, ovarian resident cells and immune cells form a complex interaction network through metabolite exchange and inflammatory signals, which mutually drive each other together with epigenetic modifications, forming a vicious cycle. Specifically, there is a significant accumulation of MNGCs in aging ovaries. These cells highly express lipid degradation-related genes such as LIPA, as well as pro-inflammatory immune molecules including IL-6 and TNF-α, directly shaping a local microenvironment that favors inflammation and tissue remodeling.115 In this microenvironment, the function of pro-inflammatory M1 macrophages is enhanced, while the function of reparative M2 macrophages (which rely on OXPHOS) is impaired—further forming a positive feedback loop between inflammation and metabolic imbalance. Abnormal metabolite accumulation is the core driver coupling epigenetic and immune responses. For example, the dyshomeostasis of FTO-dependent metabolites such as succinate inhibits the demethylase activity of FTO,116 leading to increased m6A modification and decreased mRNA stability of key pro-apoptotic genes, while relieving the inhibition of genes involved in excessive follicular activation. This directly accelerates the exhaustion of the primordial follicle pool and remodels the ovarian immune microenvironment.117 This pathway clearly demonstrates how metabolic disorders simultaneously affect cell fate and immune homeostasis by modifying the RNA epigenetic landscape. Furthermore, depletion of the energy hub NAD+ inhibits the activity of deacetylases such as SIRTs, resulting in increased histone acetylation and activation of the NF-κB pathway, which collectively drive the release of SASP factors.118,119 Conversely, inflammatory signals (such as sustained activation of the NF-κB pathway) can also induce extensive abnormalities in epigenetic modifications and further suppress the functions of metabolic pathways including OXPHOS, thereby forming a “metabolism-immunity-epigenetics” triangular crosstalk network.114 Recent spatiotemporal transcriptomic studies on primate ovaries have also systematically confirmed that metabolic reprogramming, immune cell infiltration, and epigenetic changes exhibit significant three-dimensional synergetic characteristics during aging.120 This indicates that metabolic disorders can collectively amplify inflammatory responses via diverse epigenetic mechanisms.
Within this network, epigenetic regulation also directly affects immune recognition. For instance, the bromodomain protein BRD4 is recruited to senescence-associated super-enhancer regions, strongly activating the expression of pro-inflammatory factor genes while upregulating MHC-I molecules. This promotes the recognition and clearance of senescent cells by CD8+ T cells and natural killer cells, forming a “senescent cell immune surveillance” mechanism.121 In addition, external factors such as gut microbial metabolites are also involved in this network. Butyrate, a beneficial short-chain fatty acid, can inhibit HDAC and enhance SIRT1 activity to antagonize the NF-κB pathway; in contrast, lipopolysaccharides produced by gut dysbiosis exacerbate oxidative stress and insulin resistance by activating toll-like receptor 4 (TLR4) signaling.122 Cross-tissue studies further confirm that activation of the complement-immunoglobulin axis and epigenetic reprogramming of fatty acid metabolism driven by gut dysbiosis are among the key hubs of systemic aging in mammals.123 It is important to emphasize that exogenous toxins (e.g., triptolide) can also induce the leakage of mtDNA into the cytoplasm, activating the cGAS-STING pathway to trigger ovarian innate immune inflammatory responses. Epigenetic dysregulation, verified by techniques such as reduced representation bisulfite sequencing, ultimately leads to abnormal oocyte spindles and decreased quality.124 Integrating metabolomic, epigenomic, and transcriptomic data using spatiotemporal multi-omics technologies will enable more precise dissection of the core interaction hubs in this three-level regulatory network, providing accurate guidance for the development of ovary-specific intervention strategies.125 In summary, ovarian aging is largely the result of the interaction between metabolic reprogramming and its core characteristics within the framework of the “metabolism-immunity-epigenetics” triangular network. Ultimately, multi-cascade cycles lead to irreversible decline in ovarian function. (Figure 3). The complex interaction relationships of the metabolism-epigenetics-immunity triangular network are shown in Table 3.
Figure 3.
The metabolic-immune-epigenetic crosstalk network drives ovarian aging
This model illustrates the self-reinforcing triangular network that orchestrates ovarian functional decline. The core mechanism involves metabolic reprogramming (e.g., mitochondrial dysfunction, glycolytic shift, and NAD+ depletion), which generates metabolites such as lactate. These metabolites in turn induce epigenetic modifications (e.g., histone lactylation). These modifications promote the formation of a pro-inflammatory gene expression profile and drive chronic immune-inflammation characterized by SASP secretion and immune cell infiltration. Crucially, this inflammatory state feedback exacerbates metabolic and epigenetic dysregulation, forming a vicious cycle that accelerates follicular atresia and hormonal decline. Abbreviations are defined as follows: POAT, peri-ovarian adipose tissue; MHC-I, major histocompatibility complex class I; NLRP3, NOD-like receptor thermal protein domain associated protein 3; HDAC4, histone deacetylase 4; dNTPs, deoxyribonucleoside triphosphates; HDR, homology-directed repair; BRD4, bromodomain-containing protein 4; AP-1, activator protein 1; TEAD1, TEA domain transcription factor 1.
Table 3.
Metabolic-epigenetic-immune triangular network crosstalk
| Direction of crosstalk | Core molecular events | Regulatory effects | Association | Reference |
|---|---|---|---|---|
| Metabolism ↔ epigenetics | DNMT1 → enhances mtDNA methylation | Inhibits respiratory chain gene expression → mitochondrial dysfunction | Oocyte maturation | He et al.84 |
| Activation of RORα→SOD/GPX promoter demethylation | Enhances antioxidant defense → mitigates oocyte quality decline | Oocyte quality | Fang et al.85 | |
| Lactate accumulation→ high-lactate microenvironment | Histone lactylation modification | Meiotic errors | Liu et al.; Zhang et al.38,88 | |
| lncRNA+recruitment of HDAC4 inhibits transcription | Drive metabolic reprogramming | GCs proliferative defect | Grossi et al.; Li et al.89,90 | |
| m6A methylation→mRNA | Affect protein synthesis | Oocyte aging phenotype | Jiang et al.91 | |
| NAD+ depletion→SIRT inactivation | ROS accumulation, OXPHOS impairment | Oocyte apoptosis | Yang et al.; Zhu et al.101,103 | |
| Metabolism ↔ immunity |
Increased pro-inflammatory macrophage infiltration → local ovarian inflammation | Lipotoxic microenvironment | Abnormal follicular development | Leeners et al.42 |
| Complement-immunoglobulin Axis activation | Epigenetic reprogramming of fatty acid metabolism | Mammalian aging | Zhang et al.123 | |
| Epigenetics↔ immunity |
Aging-related enhancer | Activation→pro-inflammatory factors and MHC-I | Immune surveillance of senescent cells | Tasdemir et al.121 |
| Inhibition of HDAC → enhanced activity of SIRT1 | Suppresses NF-κB pathway and inflammation | Inflammatory microenvironment | Huang et al.122 | |
| The three component crosstalk network | NAD+ depletion → inhibition of SIRTs activity | Increased histone acetylation and NF-κB activation → SASP secretion | SASP secretion in aging ovaries | Ahmed et al.24 |
| Epigenetic enzymes → proinflammatory factors | Drives metabolic reprogramming and SASP | decreased HDR efficiency; aging | Di Giorgio et al.; Liu et al.86,114 | |
| Gut dysbiosis (e.g., LPS) → TLR4 activation | Drives proinflammatory signaling → oxidative stress | Exacerbate oxidative stress | Huang et al.122 | |
| Exogenous toxins → mtDNA leakage → cGAS-STING activation | Triggers innate immune response and epigenetic dysregulation | Decline in oocyte quality | Cheng et al.124 | |
| SASP → inhibits mitochondrial OXPHOS | Inhibits OXPHOS and amplifies local inflammation | Acceleration of follicular atresia | Suda et al.126 |
Intervention strategies targeting metabolic reprogramming
Mitochondrial-targeted intervention and replacement strategies
Mitochondrial dysfunction is a core driver of ovarian aging, which can trigger energy crisis and oxidative stress, leading to follicular reserve depletion.127 Its intervention strategies mainly include two approaches: “functional regulation” and “mitochondrial replacement.” In terms of functional regulation, targeted improvement of mitochondrial quality has potential value. For example, FSH enhances mitochondrial function and energy supply in the aging ovary by activating PINK1/Parkin-mediated mitophagy and AMPK/mTOR-regulated glycophagy.128 The mitochondrial quality control (MQC) system, which includes autophagy, dynamics, and biosynthesis, is highly conserved in mammalian oocytes. Optimizing MQC through antioxidants or metabolic modulators can effectively improve oocyte developmental potential and reproductive efficiency.129 In addition, with aging, mitochondrial dynamics tend to excessive fission. Regulating key dynamic proteins using mitochondrial fission inhibitors, fusion promoters, or autophagy inducers can reduce mitochondrial fragmentation, thereby improving oocyte quality.130
On the other hand, mitochondrial heteroplasmy (the ratio of wild-type to mutant mtDNA) serves as a key factor determining oocyte fate. Once the accumulation of harmful mutations exceeds the functional threshold, it triggers the collapse of OXPHOS and the loss of developmental potential, thereby laying a theoretical foundation for mitochondrial replacement therapy (MRT), particularly spindle transfer (ST). This technique reconstructs the basis of energy metabolism by transplanting the nuclear genetic material of a patient’s oocyte into the cytoplasm of a donor oocyte containing healthy mtDNA with low heteroplasmy.131 The prototype of this technique can be traced back to the successful case of ooplasmic transfer in 1997.132 Recent clinical studies have further shown that maternal ST can promote blastocyst formation in the treatment of couples with idiopathic infertility and repeated in vitro fertilization failure, preliminarily confirming its potential clinical application in specific types of infertility.133 In addition, a follow-up study on 17 offspring conceived via MRT conducted by Chen et al. showed that these offspring were in good health, providing preliminary evidence for the safety of the technique; however, long-term and systematic monitoring is still advocated.134 These advances suggest that MRT has transcended the scope of genetic disease prevention and is expected to become a new strategy for restoring oocyte quality and extending reproductive lifespan by reversing age-related mitochondrial dysfunction.135 Nevertheless, its clinical translation still faces severe ethical and regulatory challenges. A survey of experts in mitochondrial diseases in Germany revealed that although the academic community holds a cautiously optimistic attitude, there is widespread concern about the social and regulatory risks posed by heritable gene editing. It also emphasizes that sufficient safety and efficacy data must be accumulated before widespread application.136
Regulation of core energy metabolism hubs
Competitive inhibition of HK—the rate-limiting enzyme of glycolysis—can block the glycolytic pathway and activate AMPK. As a sensor of energy and metabolic stress, AMPK acts as a “brake” in maintaining follicle quiescence. It blocks the activation of the PI3K-Akt pathway by inhibiting mTORC1 signaling and maintains the nuclear activity of FoxO3a, thereby preventing premature activation and depletion of primordial follicles.137 Caloric restriction delays ovarian aging by inhibiting mTOR and activating the SIRT1 signaling pathway, which reduces excessive activation and loss of primordial follicles. Its potential downstream mechanisms include enhancing mitochondrial function and reducing ROS production.138 Adjusting the proportion of dietary macronutrients is a new direction for precise metabolic intervention: restricting BCAA intake can inhibit excessive activation of mTORC1 and delay GC senescence; increasing the proportion of Omega-3 PUFAs (e.g., docosahexaenoic acid) reduces the secretion of SASP factors by inhibiting the NF-κB pathway, thereby improving inflammation in the follicular microenvironment.139 α-KG—an intermediate metabolite of the TCA cycle—serves as a cofactor for epigenetic modification enzymes. It can reduce senescence markers such as H3K9me3, increase NAD+ levels, and activate SIRT1; direct supplementation of α-KG can significantly delay ovarian aging and extend the reproductive lifespan of aged female mice.76 Targeting NAD+ metabolism is one of the core strategies for intervening in energy hubs. Gain-of-function studies have shown that targeting nicotinamide phosphoribosyltransferase (NAMPT)—the rate-limiting enzyme in NAD+ biosynthesis—can effectively increase NAD+ levels and improve mitochondrial function in aged oocyte models.140 Among NAD+ precursors, NMN has shown potential in the anti-aging field. Early human clinical trials focusing on age-related metabolic indicators have demonstrated its good safety and tolerability,141 laying a safety foundation for its application in reproductive medicine. In addition, engineered biomaterials can overcome the delivery bottleneck of metabolic interventions. For example, ROS-responsive hydrogels loaded with nicotinamide riboside—another NAD+ precursor—enable sustained local release of NAD+ in the ovary, avoiding the first-pass effect and off-target risks of systemic administration; mitochondrial-targeted nanoparticles encapsulating α-lipoic acid can specifically scavenge ROS in oocyte mitochondria, with an efficiency several times higher than that of traditional antioxidants.142 Although most precise delivery technologies are still in the preclinical stage, their rapid development opens up avenues for the efficient delivery of metabolic regulators (such as NAD+ precursors) to ovarian targets, holding promise for translation into personalized treatment regimens.
Lipid peroxidation and ferroptosis blockade
Ferroptosis is involved in oocyte quality decline and GC dysfunction; targeted inhibition of ferroptosis is one of the key strategies for protecting ovarian reserve.143 For example, three-dimensionally cultured mesenchymal stem cells (MSCs) spheres enhance antioxidant capacity by synergistically activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, and regulate iron homeostasis by increasing ferritin/transferrin 1. This can effectively inhibit ferroptosis in ovarian GCs and restore ovarian function.144 Plant-derived compound preparations precisely regulate arachidonic acid metabolism in the core lipid peroxidation pathway of ferroptosis and the Akt survival signaling pathway, significantly inhibiting GC ferroptosis and reversing reproductive function in POF models. This provides new evidence for the development of natural anti-ferroptosis therapies.145 In addition, acupuncture—as a non-pharmacological intervention—improves SOD/GSH peroxidase activity, reverses mitochondrial dysfunction, inhibits glycolysis activation and ferroptosis, and synergistically improves ovarian function in chemotherapy-induced POF models. This offers a new strategy for clinical translation.146
Stem cell-mediated microenvironment reconstruction
Stem cells play a key role in ovarian tissue repair, and the microenvironment reconstruction mediated by them is an important mechanism for functional recovery. Human embryonic stem cells can be induced to differentiate into ovarian follicle-like cells in vitro, including oocytes and GCs.147 MSCs activate signaling pathways related to follicle development through paracrine secretion of various bioactive factors. Meanwhile, they exert antioxidant, anti-inflammatory, and pro-angiogenic effects, thereby improving the homeostasis of the ovarian microenvironment, inhibiting GC apoptosis, and promoting the reconstruction of ovarian structure and function.148 Beyond the classical paracrine mechanism, exosomes derived from MSCs exhibit significant therapeutic potential. On one hand, they can activate the Nrf2/GPX4 antioxidant pathway in GCs to inhibit ferroptosis, improve mitochondrial function, and reduce lipid peroxidation—thereby restoring ovarian function and fertility in mice with chemotherapy-induced POI149; on the other hand, exosomal miR-143-3p and miR-155-5p derived from follicular fluid can target and inhibit the expression of HK2, a key glycolytic enzyme, thereby reducing the glycolytic activity of GCs and impairing follicular development.150 Furthermore, exosomes derived from human amniotic MSCs can deliver miR-320a, which reduces the production of mitochondrial ROS by targeting and inhibiting SIRT4, thereby alleviating oxidative stress in GCs and improving ovarian function in POI models.151 Collectively, these findings reveal that exosomes and their carried miRNAs can regulate follicular quality through multiple pathways. Current bioengineering strategies have significantly improved the precision of stem cell-mediated metabolic regulation. For example, enhancing the mitochondrial transfer capacity of stem cells through gene editing, or designing biomimetic exosomes for targeted delivery of key metabolic enzymes such as SOD2 and NAMPT, can effectively overcome the limitations of traditional therapies.152 The exosome engineering strategy of hypoxic preconditioning for MSCs can efficiently restore the metabolic coupling between glycolysis and oocytes by targeting and regulating LDHA activity in GCs. This strategy avoids complex genetic manipulation and has greater potential for clinical translation.153 In addition, implantable ovarian regeneration patches derived from stem cells improve the local microenvironment and activate residual follicles through paracrine effects, significantly restoring ovarian endocrine function and fertility in a rat model of POI.154 Notably, cell-free fat extract—an enriched preparation of active components from the secretome of adipose-derived stem cells—can avoid the risks of cell transplantation. By delivering factors such as SOD3 and fibroblast growth factor 2 (FGF2) to improve GCs mitochondrial function and inhibit the SASP, it provides a safer intervention option for DOR.155 The underlying mechanisms of these strategies may involve stem cells synergistically regulating metabolic reprogramming and epigenetic remodeling to reverse the aging microenvironment. This metabolic-epigenetic crosstalk network constitutes the core theoretical basis for stem cells to delay ovarian aging.156
Senescent cell clearance and inflammatory circuit blockade
Senescent cells accumulated in the ovary are key nodes driving the metabolic-inflammatory vicious cycle. Their unique SASP inhibits the mitochondrial OXPHOS function of GCs by releasing pro-inflammatory factors and activates the NF-κB signaling pathway to amplify local inflammation. Meanwhile, the metabolic reprogramming of senescent cells themselves further disrupts the energy homeostasis of follicular units. Therefore, clearing senescent cells and blocking inflammatory circuits are key strategies for intervening in ovarian dysfunction.126 Preclinical studies have confirmed that senescent cells resist clearance through anti-apoptotic pathways such as BCL-2/BCL-XL and immune evasion mechanisms. Senolytic drugs can break through this barrier. One category is combination regimens like dasatinib/quercetin, which selectively clear senescent GCs by targeting anti-apoptotic pathways; the other category includes JAK inhibitors such as ruxolitinib, which target SASP signals to block the secretion of pro-inflammatory factors like IL-6/IL-8.157 Notably, senescent cells may be associated with insulin resistance and lipid metabolism disorders through the secretion of SASP factors, while senolytic treatment can improve systemic metabolic homeostasis.158 In terms of clinical application, the clinical translation of senolytics is addressing potential safety issues through strategies such as intermittent administration and targeted delivery, to minimize off-target effects on normal tissues.159 Against this backdrop, a phase II clinical trial for POI reported that FIS001—the first targeted nanogel formulation loaded with dasatinib/quercetin—was administered locally via the vagina. After three months of treatment, it significantly increased the number of antral follicles and elevated AMH levels in patients, with no serious systemic adverse reactions reported.159 In addition, apigenin, a natural flavonoid compound, can selectively clear senescent GCs with high p16INK4a expression and inhibit the SASP. In a chemotherapy-induced ovarian injury model, its single-drug treatment improved ovarian function, and no side effects common to traditional senolytics (such as myelosuppression) were observed.160 Beyond direct clearance strategies, reversing the function of senescent cells is emerging as a novel intervention paradigm. By regulating key transcription factor networks (e.g., AP-1) and epigenetic modifications (e.g., histone H3 lysine 27 trimethylation, H3K27me3), it is promising to restore the metabolic homeostasis and secretory phenotype of senescent GCs, prompting them to exit the senescent state—rather than directly eliminating the cells. This provides a new approach for developing therapies with greater ovarian protective effects.161
Epigenetic reprogramming intervention strategies
Epigenetic regulation plays a crucial role in reversing reproductive aging, with its core mechanism lying in the integration of a multi-dimensional targeting framework of “epigenetics-metabolism-inflammation.” Specifically, epigenetic modifications repair metabolic dysfunction by activating mitochondria-related genes such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha and SIRT3; meanwhile, they protect germ cells from inflammatory damage by inhibiting the SASP and the NLRP3 inflammasome, thereby providing translational potential for ovarian function protection.162 Epigenetic reprogramming synergistically repairs metabolic dysfunction through multiple pathways. For example, histone acetyltransferases promote glycolysis/OXPHOS balance to maintain germ cell metabolic vitality; targeting H3K27me3 or inhibiting the release of inflammatory factors such as IL-6 can synergistically reverse germ cell senescence.163 Dietary restriction effectively protects DNA methylation from age-related changes by enhancing nutrient-sensing pathways, and reprograms lipid metabolism by remodeling genome-wide DNA methylation, thereby delaying the aging process.164 Targeted correction of non-coding RNA dysregulation can restore mitochondrial function, improve energy metabolism, reduce ROS production, reshape metabolic homeostasis, and reverse the reproductive aging phenotype.165 In addition, Yamanaka factor-mediated chromatin remodeling resets the epigenetic clock by transiently activating transcription factors such as octamer-binding transcription factor 4 (OCT4)/sex-determining region Y-box transcription factor 2 (SOX2), restoring the metabolic and repair capabilities of ovarian cells and providing a breakthrough strategy for delaying reproductive aging.166 In summary, epigenetic modifications regulate metabolic reprogramming, inflammation, and aging processes through epigenetic enzymes (such as HDACs/DNMTs), chromatin remodeling complexes (such as SWI/SNF), and non-coding RNA networks. This provides a unified theoretical basis for the development of precise intervention strategies for ovarian aging.167 (Figure 4). Intervention strategies targeting metabolic reprogramming and their clinical translation potential are shown in Table 4.
Figure 4.
Comprehensive intervention strategies targeting metabolic reprogramming to delay ovarian aging
This integrative schematic summarizes five core therapeutic avenues. (1) Metabolic hub regulation centers on improving energy homeostasis via NAD+ precursors, caloric restriction, and biomaterial-based delivery systems to inhibit overactive nutrient-sensing pathways. (2) Ferroptosis blockade utilizes compounds like AdipoRon and stem cells to inhibit lipid peroxidation by modulating the ACSL4/GPX4 axis and enhancing antioxidant defenses. (3) Senescent cell clearance applies senolytics and natural flavonoids to eliminate pro-inflammatory senescent cells, thereby disrupting the SASP-fueled vicious cycle. (4) Epigenetic reprogramming employs dietary regulators, non-coding RNAs, and chromatin modifiers to reverse age-related gene expression patterns. (5) Stem cell-mediated microenvironment reconstruction leverages various stem cell sources and their secretomes to promote tissue repair, reduce oxidative stress, and restore metabolic coupling. Collectively, these strategies aim to intercept the metabolic dysregulation that drives ovarian aging at multiple nodal points. Abbreviations are defined as follows: Nrf2, nuclear factor erythroid 2-related factor 2; STEAP3: six-transmembrane epithelial antigen of the prostate 3; MSCs, mesenchymal stem cells; DMT1: divalent metal transporter 1; TfR1: transferrin receptor 1; Cys, cysteine; Glu, glutamate; Gly, glycine; GSH, glutathione; PUFA, polyunsaturated fatty acid; α-KG, alpha-ketoglutarate; DHA, docosahexaenoic acid; SWI/SNF: a chromatin remodeling complex (SWItch/sucrose non-fermentable).
Table 4.
Metabolic reprogramming-targeted interventions and translation
| Intervention category | Representative strategies | Action targets | Experimental evidence | Reference |
|---|---|---|---|---|
| Energy regulation | Supplementation with NMN/NR | NAD+; SIRT1/3/6 | Delay reproductive aging | Kordowitzki et al.; Xie et al.70,141 |
| Inhibition of HK | AMPK/mTORC1/PI3K-Akt | Reduction of primordial follicle activation | Zhang et al.137 | |
| Caloric restriction | mTOR/SIRT | Delay ovarian aging | Wang et al.138 | |
| Adjusting dietary macronutrients | BCAA/mTORC1/SASP | Improving microenvironmental inflammation and GCs senescence | Calubag et al.139 | |
| Supplementation of α-KG | NAD+/SIRT | Slow down ovarian aging in aged female mice | Zhang et al.76 | |
| Targeted biomaterials | NAD+/ROS | Improve antioxidant efficiency | Wu et al.142 | |
| Mitochondrial replacement | Spindle transfer (ST) | Mutant mtDNA (heteroplasmy) | Reconstructed oocytes → successful blastocyst formation in idiopathic infertility/IVF failure patients. | Zhou et al.; Costa-Borges et al.131,133 |
| Ooplasmic transfer | Oocyte cytoplasm (mitochondria) | Prototype technique traced back to a successful case in 1997. | Cohen et al.132 | |
| Block ferroptosis | Liproxstatin-1 | GPX4/ACSL4 | Improve oocyte quality | Zeng et al.54 |
| Melatonin upregulation | GPX4 | Inhibition of oocyte ferroptosis | Tsui et al.58 | |
| AdipoRon | ACSL4/PUFA | Block the ferroptosis cascade | Zhou et al.59 | |
| Engineering strategies | Ferritin/Transferrin 1 | Inhibition of GCs ferroptosis | Xu et al.144 | |
| Plant compound formula | Arachidonic Acid/Akt | Inhibition of ferroptosis, reversal of POF | Dang et al.145 | |
| Acupuncture | GPX4/ACSL4 axis | Inhibition of glycolytic activation and ferroptosis | Dandan et al.146 | |
| Stem cells | MSCs | Active factors | Promote ovarian reconstruction | Li et al.148 |
| Engineered exosomes | SOD2/NAMPT et al. | Enhancing metabolic regulation of stem cells | Francés-Herrero et al.152 | |
| Hypoxic preconditioned exosomes | Targeting LDHA | Restore the metabolic coupling between glycolysis and oocytes | Li et al.153 | |
| Regenerative patch | Paracrine | Improve ovarian endocrine function | Zhang et al.154 | |
| Cell-free extract | SOD3、FGF2 et al. | Improve mitochondrial function | Liu et al.155 | |
| Clearance of senescent cells | Dasatinib/quercetin | BCL-2/BCL-XL | Clearance of senescent GCs | Secomandi et al.157 |
| Ruxolitinib | SASP | Block the secretion of IL-6/IL-8 and other proinflammatory factors | Secomandi et al.157 | |
| FIS001 (dasatinib/quercetin-loaded nanogel) | Senescent cells (local delivery) | Phase II trial for POI: vaginal administration → increased antral follicle count and AMH levels after 3 months. | Chaib et al.159 | |
| Apigenin | PI3K/Akt | Clearance of senescent GCs and reduction of SASP factors | Zhang et al.160 | |
| Epigenetics | Activation of mitochondrial genes | SIRTs/SASP | Protect germ cells | Winstanley et al.162 |
| Epigenetic enzyme | H3K27me3/IL-6/OXPHOS | Balancing and reversing germ cell aging | Ji et al.; Wang et al.163,167 | |
| Dietary restriction | DNA methylation (genome-wide) | Delay the aging process | Hahn et al.164 | |
| ncRNA | Mitochondria-related | Reverse the reproductive aging phenotype | Huang et al.165 | |
| Yamanaka | OCT4/SOX2 factors | Reset the epigenetic clock | Pereira et al.166 |
Identification and validation of intervention targets based on multi-omics technologies
The integration of multi-omics technologies provides a powerful tool for analyzing the heterogeneity of the follicular microenvironment and identifying intervention targets. As a cutting-edge tool in aging research, spatial omics, combined with metabolic imaging, can accurately locate the glycolysis/OXPHOS transition zones and SASP secretion hotspots during follicle development, providing spatial coordinates for local targeted delivery strategies.168,169 Single-cell transcriptomics has successfully revealed the molecular degeneration characteristics of GCs and oocytes, as well as the mechanisms of cell communication disorders, during primate ovarian aging.170,171 It has also provided molecular pathological evidence for the toxic effects of environmental toxins on primordial follicle assembly.172 Quantitative proteomics has uncovered the dynamic changes in proteins during oocyte maturation and transition to embryos, offering a key perspective for quality regulation.173 In addition, single-cell translatomics studies have further clarified the regulatory mechanisms of translation efficiency during oocyte maturation.174 Epigenetic clock technologies (e.g., the Horvath clock) have shown potential in predicting reproductive aging. The integration of these technologies with multimodal dynamic data will provide key data support for the early warning of ovarian aging and the selection of intervention timings.175 These high-resolution technologies are driving research from static description to dynamic network analysis, laying the foundation for the development and precision of the various intervention strategies mentioned above.
Conclusion
Ovarian aging is a complex pathological process driven by dysregulated metabolic reprogramming, accompanied by the formation of a triangular vicious cycle network involving metabolic, epigenetic, and immune signals. This review systematically elaborates on how energy, lipid, and nutrient metabolic disorders synergistically drive follicular atresia and hormone synthesis failure through this network, and identifies mitochondrial dysfunction, ferroptosis, and NAD+ depletion as key molecular hubs within it. Based on these mechanisms, strategies such as mitochondria-targeted interventions, senescent cell clearance, stem cell niche reconstruction, and epigenetic regulation show potential for delaying ovarian aging.
Future research should focus on two major directions: first, constructing dynamic network models to decipher the dynamic rules of metabolism-epigenetics-immunity crosstalk by integrating multi-omics data; and second, promoting personalized clinical translation, establishing a biomarker-based ovarian function classification system, and developing targeted delivery technologies to achieve closed-loop management of “precision typing-stratified intervention-dynamic monitoring.” In conclusion, the metabolic reprogramming theory provides a new perspective for in-depth understanding of ovarian aging, and related intervention strategies are expected to serve as new approaches for improving female reproductive health.
Acknowledgments
This study was supported by the following funding sources: Hunan University of Traditional Chinese Medicine Postgraduate Research and Innovation Project (grant no. 2024CX052); Natural Science Foundation of Hunan Province (grant no. 2025JJ90029); Major Scientific Research Special Program for High-level Talents in Health and Wellness of Hunan Province (grant no. R2023168); Key Guiding Subjects of Scientific Research Projects of Hunan Provincial Health Commission (grant no. 202305017379); Scientific Research Project of Traditional Chinese Medicine of Hunan Province (grant no. B2023078); Hunan Provincial College Student Innovation and Entrepreneurship Training Program (grant no. S202510541124); Hunan Provincial Key Research and Development Program Project (grant no. 2025JK2111). The authors have received research grants from the abovementioned funding sources.
Author contributions
J.L., Q.L., and Y.Y. jointly proposed the study design and established the research framework. J.L. drafted the full manuscript. Q.L. developed the systematic literature review protocol. Y.Y. optimized the literature screening criteria and data collection methodologies. K.W. assisted in the literature search and data collection. W.L. generated figures and tables. F.Z. assisted in proofreading the final manuscript. Corresponding authors, H.L. and Y.Z. coordinated the research process, integrated substantive revisions, and ensured academic rigor throughout the preparation and submission phases.
Declaration of interests
The authors certify that no financial or nonfinancial conflicts of interest exist regarding the content of this manuscript.
Contributor Information
Huiping Liu, Email: 003433@hnucm.edu.cn.
Ye Zhang, Email: ftfyzy@163.com.
References
- 1.Liang J., Gai S., Na X., Hu J., Zhao Z., Zi D., Na Z., Gao W., Bi F., Li D. Ovarian aging at single-cell resolution: Current paradigms and perspectives. Ageing Res. Rev. 2025;110 doi: 10.1016/j.arr.2025.102807. [DOI] [PubMed] [Google Scholar]
- 2.Zhou C., Guo Q., Lin J., Wang M., Zeng Z., Li Y., Li X., Xiang Y., Liang Q., Liu J., et al. Single-Cell Atlas of Human Ovaries Reveals The Role Of The Pyroptotic Macrophage in Ovarian Aging. Adv. Sci. 2024;11 doi: 10.1002/advs.202305175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhang F., Zhu M., Chen Y., Wang G., Yang H., Lu X., Li Y., Chang H.M., Wu Y., Ma Y., et al. Harnessing omics data for drug discovery and development in ovarian aging. Hum. Reprod. Update. 2025;31:240–268. doi: 10.1093/humupd/dmaf002. [DOI] [PubMed] [Google Scholar]
- 4.Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C., Gravholt C.H., Kalantaridou S., Kallen A., Kim K.Q., et al. Evidence-based guideline: premature ovarian insufficiency. Hum. Reprod. Open. 2024;2024 doi: 10.1093/hropen/hoae065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Leone T., Brown L., Gemmill A. Secular trends in premature and early menopause in low-income and middle-income countries. BMJ Glob. Health. 2023;8 doi: 10.1136/bmjgh-2023-012312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mu L., Wang G., Yang X., Liang J., Tong H., Li L., Geng K., Bo Y., Hu X., Yang R., et al. Physiological premature aging of ovarian blood vessels leads to decline in fertility in middle-aged mice. Nat. Commun. 2025;16:72. doi: 10.1038/s41467-024-55509-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Wu C., Chen D., Stout M.B., Wu M., Wang S. Hallmarks of ovarian aging. Trends Endocrinol. Metab. 2025;36:418–439. doi: 10.1016/j.tem.2025.01.005. [DOI] [PubMed] [Google Scholar]
- 8.Touraine P., Chabbert-Buffet N., Plu-Bureau G., Duranteau L., Sinclair A.H., Tucker E.J. Premature ovarian insufficiency. Nat. Rev. Dis. Primers. 2024;10:63. doi: 10.1038/s41572-024-00547-5. [DOI] [PubMed] [Google Scholar]
- 9.Stringer J.M., Alesi L.R., Winship A.L., Hutt K.J. Beyond apoptosis: evidence of other regulated cell death pathways in the ovary throughout development and life. Hum. Reprod. Update. 2023;29:434–456. doi: 10.1093/humupd/dmad005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Zhang Z., Wu T., Sang Q. Human oocyte quality and reproductive health. Sci. Bull. 2025;70:2365–2376. doi: 10.1016/j.scib.2025.04.045. [DOI] [PubMed] [Google Scholar]
- 11.Laisk T., Tšuiko O., Jatsenko T., Hõrak P., Otala M., Lahdenperä M., Lummaa V., Tuuri T., Salumets A., Tapanainen J.S. Demographic and evolutionary trends in ovarian function and aging. Hum. Reprod. Update. 2019;25:34–50. doi: 10.1093/humupd/dmy031. [DOI] [PubMed] [Google Scholar]
- 12.Richardson M.C., Guo M., Fauser B.C.J.M., Macklon N.S. Environmental and developmental origins of ovarian reserve. Hum. Reprod. Update. 2014;20:353–369. doi: 10.1093/humupd/dmt057. [DOI] [PubMed] [Google Scholar]
- 13.Johnson J., Keefe D.L. Ovarian aging: breaking up is hard to fix. Sci. Transl. Med. 2013;5:172fs5. doi: 10.1126/scitranslmed.3005579. [DOI] [PubMed] [Google Scholar]
- 14.Fiorentino G., Cimadomo D., Innocenti F., Soscia D., Vaiarelli A., Ubaldi F.M., Gennarelli G., Garagna S., Rienzi L., Zuccotti M. Biomechanical forces and signals operating in the ovary during folliculogenesis and their dysregulation: implications for fertility. Hum. Reprod. Update. 2023;29:1–23. doi: 10.1093/humupd/dmac031. [DOI] [PubMed] [Google Scholar]
- 15.van der Reest J., Nardini Cecchino G., Haigis M.C., Kordowitzki P. Mitochondria: Their relevance during oocyte ageing. Ageing Res. Rev. 2021;70 doi: 10.1016/j.arr.2021.101378. [DOI] [PubMed] [Google Scholar]
- 16.Meng L., Coleman V., Zhao Y., Ost M., Voigt A., Bunschoten A., Keijer J., Teerds K., Klaus S. Pseudo-Starvation Driven Energy Expenditure Negatively Affects Ovarian Follicle Development. Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms22073557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gu L., Liu H., Gu X., Boots C., Moley K.H., Wang Q. Metabolic control of oocyte development: linking maternal nutrition and reproductive outcomes. Cell. Mol. Life Sci. 2015;72:251–271. doi: 10.1007/s00018-014-1739-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hayashi Y., Otsuka K., Ebina M., Igarashi K., Takehara A., Matsumoto M., Kanai A., Igarashi K., Soga T., Matsui Y. Distinct requirements for energy metabolism in mouse primordial germ cells and their reprogramming to embryonic germ cells. Proc. Natl. Acad. Sci. USA. 2017;114:8289–8294. doi: 10.1073/pnas.1620915114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wu D., Liu C., Ding L. Follicular metabolic dysfunction, oocyte aneuploidy and ovarian aging: a review. J. Ovarian Res. 2025;18:53. doi: 10.1186/s13048-025-01633-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Singh A.K., Mohanty A., Kumar S.L., Kumari A., Beniwal R., Kumar Etikuppam A., Birajdar P., Mohd A., Prasada Rao H.B.D. Diminished NAD+ levels and activation of retrotransposons promote postovulatory aged oocyte (POAO) death. Cell Death Discov. 2024;10:104. doi: 10.1038/s41420-024-01876-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Reiter R.J., Sharma R.N., Manucha W., Rosales-Corral S., Almieda Chuffa L.G.d., Loh D., Luchetti F., Balduini W., Govitrapong P. Dysfunctional mitochondria in age-related neurodegeneration: Utility of melatonin as an antioxidant treatment. Ageing Res. Rev. 2024;101 doi: 10.1016/j.arr.2024.102480. [DOI] [PubMed] [Google Scholar]
- 22.Liu T., Qu J., Tian M., Yang R., Song X., Li R., Yan J., Qiao J. Lipid Metabolic Process Involved in Oocyte Maturation During Folliculogenesis. Front. Cell Dev. Biol. 2022;10 doi: 10.3389/fcell.2022.806890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kim S.Q., Spann R.A., Hill C.M., Berryman C.E., Berthoud H.R., McDougal D.H., He Y., Münzberg H., Yu S., Morrison C.D. Protein-Restricted Diets and Their Impact on Metabolic Health and Aging. Annu. Rev. Nutr. 2025;45:269–297. doi: 10.1146/annurev-nutr-121624-114918. [DOI] [PubMed] [Google Scholar]
- 24.Ahmed M., Riaz U., Lv H., Amjad M., Ahmed S., Ali S., Ghani M.U., Hua G., Yang L. Nicotinamide Mononucleotide Restores NAD(+) Levels to Alleviate LPS-Induced Inflammation via the TLR4/NF-κB/MAPK Signaling Pathway in Mice Granulosa Cells. Antioxidants. 2024;14:39. doi: 10.3390/antiox14010039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Zheng X., Su B., Zhao Y., Chen C., Vellas B., Michel J.P., Shao R. Foundations and implications of Human Aging Omics: A framework for identifying cumulative health risks from embryo to senescence. Sci. Bull. 2024;69:3184–3187. doi: 10.1016/j.scib.2024.04.073. [DOI] [PubMed] [Google Scholar]
- 26.May-Panloup P., Boucret L., Chao de la Barca J.M., Desquiret-Dumas V., Ferré-L'Hotellier V., Morinière C., Descamps P., Procaccio V., Reynier P. Ovarian ageing: the role of mitochondria in oocytes and follicles. Hum. Reprod. Update. 2016;22:725–743. doi: 10.1093/humupd/dmw028. [DOI] [PubMed] [Google Scholar]
- 27.Liu X., Zhang X., Zhao L., Long J., Feng Z., Su J., Gao F., Liu J. Mitochondria as a sensor, a central hub and a biological clock in psychological stress-accelerated aging. Ageing Res. Rev. 2024;93 doi: 10.1016/j.arr.2023.102145. [DOI] [PubMed] [Google Scholar]
- 28.Zhang Y., Bai J., Cui Z., Li Y., Gao Q., Miao Y., Xiong B. Polyamine metabolite spermidine rejuvenates oocyte quality by enhancing mitophagy during female reproductive aging. Nat. Aging. 2023;3:1372–1386. doi: 10.1038/s43587-023-00498-8. [DOI] [PubMed] [Google Scholar]
- 29.Dong Z., Huang M., Liu Z., Xie P., Dong Y., Wu X., Qu Z., Shen B., Huang X., Zhang T., et al. Focused screening of mitochondrial metabolism reveals a crucial role for a tumor suppressor Hbp1 in ovarian reserve. Cell Death Differ. 2016;23:1602–1614. doi: 10.1038/cdd.2016.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mao Y., Zhang J., Zhou Q., He X., Zheng Z., Wei Y., Zhou K., Lin Y., Yu H., Zhang H., et al. Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation. Cell Res. 2024;34:13–30. doi: 10.1038/s41422-023-00864-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bishop A., Cartwright J.E., Whitley G.S. Stanniocalcin-1 in the female reproductive system and pregnancy. Hum. Reprod. Update. 2021;27:1098–1114. doi: 10.1093/humupd/dmab028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ben-Meir A., Burstein E., Borrego-Alvarez A., Chong J., Wong E., Yavorska T., Naranian T., Chi M., Wang Y., Bentov Y., et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. Aging Cell. 2015;14:887–895. doi: 10.1111/acel.12368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Jiang Z., Shi C., Han H., Wang Y., Liang R., Chen X., Shen H. Mitochondria-related changes and metabolic dysfunction in low prognosis patients under the POSEIDON classification. Hum. Reprod. 2021;36:2904–2915. doi: 10.1093/humrep/deab203. [DOI] [PubMed] [Google Scholar]
- 34.Wu Y., Zhang Z., Xu Y., Zhang Y., Chen L., Zhang Y., Hou K., Yang M., Jin Z., Cai Y., et al. A high-resolution N-glycoproteome landscape of aging mouse ovary. Redox Biol. 2025;81 doi: 10.1016/j.redox.2025.103584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Morimoto A., Rose R.D., Smith K.M., Dinh D.T., Umehara T., Winstanley Y.E., Shibahara H., Russell D.L., Robker R.L. Granulosa cell metabolism at ovulation correlates with oocyte competence and is disrupted by obesity and aging. Hum. Reprod. 2024;39:2053–2066. doi: 10.1093/humrep/deae154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Marynowicz W., Głód P., Maduzia D., Gogola-Mruk J., Ptak A. Energy imbalance in oPOI ovarian granulosa cells is linked to reduced glucose bioavailability and metabolism. Reprod. Biol. Endocrinol. 2025;23:96. doi: 10.1186/s12958-025-01426-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Emidio G.D., Placidi M., Rea F., Rossi G., Falone S., Cristiano L., Nottola S., D'Alessandro A.M., Amicarelli F., Palmerini M.G., Tatone C. Methylglyoxal-Dependent Glycative Stress and Deregulation of SIRT1 Functional Network in the Ovary of PCOS Mice. Cells. 2020;9 doi: 10.3390/cells9010209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Liu K., Wei H., Nong W., Peng H., Li Y., Lei X., Zhang S. Nampt/SIRT2/LDHA pathway-mediated lactate production regulates follicular dysplasia in polycystic ovary syndrome. Free Radic. Biol. Med. 2024;225:776–793. doi: 10.1016/j.freeradbiomed.2024.10.312. [DOI] [PubMed] [Google Scholar]
- 39.Hao J., Li T., Heinzelmann M., Moussaud-Lamodière E., Lebre F., Krjutškov K., Damdimopoulos A., Arnelo C., Pettersson K., Alfaro-Moreno E., et al. Effects of chemical in vitro activation versus fragmentation on human ovarian tissue and follicle growth in culture. Hum. Reprod. Open. 2024;2024:hoae028. doi: 10.1093/hropen/hoae028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Yang H.L., Chang C.W., Vadivalagan C., Pandey S., Chen S.J., Lee C.C., Hseu J.H., Hseu Y.C. Coenzyme Q(0) inhibited the NLRP3 inflammasome, metastasis/EMT, and Warburg effect by suppressing hypoxia-induced HIF-1α expression in HNSCC cells. Int. J. Biol. Sci. 2024;20:2790–2813. doi: 10.7150/ijbs.93943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Dri M., Klinger F.G., De Felici M. The ovarian reserve as target of insulin/IGF and ROS in metabolic disorder-dependent ovarian dysfunctions. Reprod. Fertil. 2021;2:R103–R112. doi: 10.1530/RAF-21-0038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Leeners B., Geary N., Tobler P.N., Asarian L. Ovarian hormones and obesity. Hum. Reprod. Update. 2017;23:300–321. doi: 10.1093/humupd/dmw045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Dipali S.S., Ferreira C.R., Zhou L.T., Pritchard M.T., Duncan F.E. Histologic analysis and lipid profiling reveal reproductive age-associated changes in peri-ovarian adipose tissue. Reprod. Biol. Endocrinol. 2019;17:46. doi: 10.1186/s12958-019-0487-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Wu M., Huang Y., Zhu Q., Zhu X., Xue L., Xiong J., Chen Y., Wu C., Guo Y., Li Y., et al. Adipose tissue and ovarian aging: Potential mechanism and protective strategies. Ageing Res. Rev. 2022;80 doi: 10.1016/j.arr.2022.101683. [DOI] [PubMed] [Google Scholar]
- 45.Wołodko K., Castillo-Fernandez J., Kelsey G., Galvão A. Revisiting the Impact of Local Leptin Signaling in Folliculogenesis and Oocyte Maturation in Obese Mothers. Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms22084270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Shang Y., Li Y., Han D., Deng K., Gao W., Wu M. LRRC4 Deficiency Drives Premature Ovarian Insufficiency by Disrupting Metabolic Homeostasis in Granulosa Cells. Adv. Sci. 2025;12 doi: 10.1002/advs.202417717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Pan B., Qin J., Du K., Zhang L., Jia G., Ye J., Liang Q., Yang Q., Zhou G. Integrated ultrasensitive metabolomics and single-cell transcriptomics identify crucial regulators of sheep oocyte maturation and early embryo development in vitro. J. Adv. Res. 2025;73:147–160. doi: 10.1016/j.jare.2024.08.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.van Oortmerssen J.A.E., Mulder J.W.C.M., Kavousi M., Roeters van Lennep J.E. Lipid metabolism in women: A review. Atherosclerosis. 2025;405 doi: 10.1016/j.atherosclerosis.2025.119213. [DOI] [PubMed] [Google Scholar]
- 49.Yu Y., Shan Y., Lu J., Xian Y., Tang Z., Guo X., Huang Y., Ni X. Ferroptosis and Sterol Biosynthesis Dysregulation in Granulosa Cells of Patients with Diminished Ovarian Reserve. Antioxidants. 2025;14 doi: 10.3390/antiox14060749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Chen H., Wang Q., Zhang Y., Shangguan L., Zhu Z., Zhang H., Zou X., Geng Q., Wen Y., Wang D., Wang Y. Loss of vitamin D receptor induces premature ovarian insufficiency through compromising the 7-dehydrocholesterol-dependent anti-aging effects. Front. Cell Dev. Biol. 2025;13 doi: 10.3389/fcell.2025.1545167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Converse A., Perry M.J., Dipali S.S., Isola J.V.V., Kelly E.B., Varberg J.M., Zelinski M.B., Stout M.B., Pritchard M.T., Duncan F.E. Multinucleated giant cells are hallmarks of ovarian aging with unique immune and degradation-associated molecular signatures. PLoS Biol. 2025;23 doi: 10.1371/journal.pbio.3003204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Magdalena P., Olga K.J., Anna P., Robert J. Unfavorably altered lipid profile in women with primary ovarian insufficiency. J. Clin. Lipidol. 2024;18:e602–e609. doi: 10.1016/j.jacl.2024.04.125. [DOI] [PubMed] [Google Scholar]
- 53.Yang P.K., Chou C.H., Huang C.C., Wen W.F., Chen H.F., Shun C.T., Ho H.N., Chen M.J. Obesity alters ovarian folliculogenesis through disrupted angiogenesis from increased IL-10 production. Mol. Metab. 2021;49 doi: 10.1016/j.molmet.2021.101189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Zeng W., Wang F., Cui Z., Zhang Y., Li Y., Li N., Mao Z., Zhang H., Liu Y., Miao Y., et al. Inhibition of ferroptosis counteracts the advanced maternal age-induced oocyte deterioration. Cell Death Differ. 2025;32:1071–1085. doi: 10.1038/s41418-025-01456-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Li L., Dong Y., Zhao J., Li Y., Wang Z., Liu B., Chen J., Wang T., Gao H., Xiao X., et al. Effects and mechanisms of aflatoxin B1 on oocytes and embryo development. Ecotoxicol. Environ. Saf. 2025;302 doi: 10.1016/j.ecoenv.2025.118572. [DOI] [PubMed] [Google Scholar]
- 56.Zhang S., Liu Q., Chang M., Pan Y., Yahaya B.H., Liu Y., Lin J. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis. 2023;14:340. doi: 10.1038/s41419-023-05859-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Shelling A.N., Ahmed Nasef N. The Role of Lifestyle and Dietary Factors in the Development of Premature Ovarian Insufficiency. Antioxidants. 2023;12 doi: 10.3390/antiox12081601. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Tsui K.H., Li C.J., Lin L.T. Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age. Reprod. Biol. Endocrinol. 2024;22:138. doi: 10.1186/s12958-024-01311-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Zhou Y., Zhang S., Jia Y., Wang X., Liu Y., Zhang H., Yuan Z., Han Y., Weng Q. Regulation and Role of Adiponectin Secretion in Rat Ovarian Granulosa Cells. Int. J. Mol. Sci. 2024;25 doi: 10.3390/ijms25105155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Zeng Q., Gong Y., Zhu N., Shi Y., Zhang C., Qin L. Lipids and lipid metabolism in cellular senescence: Emerging targets for age-related diseases. Ageing Res. Rev. 2024;97 doi: 10.1016/j.arr.2024.102294. [DOI] [PubMed] [Google Scholar]
- 61.Al Rashid K., Taylor A., Lumsden M.A., Goulding N., Lawlor D.A., Nelson S.M. Association of the functional ovarian reserve with serum metabolomic profiling by nuclear magnetic resonance spectroscopy: a cross-sectional study of ∼400 women. BMC Med. 2020;18:247. doi: 10.1186/s12916-020-01700-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Liu H., Tian Z., Guo Y., Liu X., Ma Y., Du X., Wang R., Zhang S., Shi L., Guo H., Zhang H. Microcystin-leucine arginine exposure contributes to apoptosis and follicular atresia in mice ovaries by endoplasmic reticulum stress-upregulated Ddit3. Sci. Total Environ. 2021;756 doi: 10.1016/j.scitotenv.2020.144070. [DOI] [PubMed] [Google Scholar]
- 63.Zhang K.H., Jiao L., Wang Y., Sun S.C. Arf6 GTPase deficiency leads to porcine oocyte quality decline during aging. FASEB J. 2024;38 doi: 10.1096/fj.202400893R. [DOI] [PubMed] [Google Scholar]
- 64.Bao S., Yin T., Liu S. Ovarian aging: energy metabolism of oocytes. J. Ovarian Res. 2024;17:118. doi: 10.1186/s13048-024-01427-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Jia L., Zeng Y., Hu Y., Liu J., Yin C., Niu Y., Wang C., Li J., Jia Y., Hong J., Zhao R. Homocysteine impairs porcine oocyte quality via deregulation of one-carbon metabolism and hypermethylation of mitochondrial DNA. Biol. Reprod. 2019;100:907–916. doi: 10.1093/biolre/ioy238. [DOI] [PubMed] [Google Scholar]
- 66.Harasimov K., Gorry R.L., Welp L.M., Penir S.M., Horokhovskyi Y., Cheng S., Takaoka K., Stützer A., Frombach A.S., Taylor Tavares A.L., et al. The maintenance of oocytes in the mammalian ovary involves extreme protein longevity. Nat. Cell Biol. 2024;26:1124–1138. doi: 10.1038/s41556-024-01442-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Zou X., Liang X., Dai W., Zhu T., Wang C., Zhou Y., Qian Y., Yan Z., Gao C., Gao L., et al. Peroxiredoxin 4 deficiency induces accelerated ovarian aging through destroyed proteostasis in granulosa cells, Biochimica et biophysica acta. Mol. Basis Dis. 2024;1870 doi: 10.1016/j.bbadis.2024.167334. [DOI] [PubMed] [Google Scholar]
- 68.Liu C., Dou Y., Zhang M., Han S., Hu S., Li Y., Yu Z., Liu Y., Liang X., Chen Z.J., et al. High-fat and high-sucrose diet impairs female reproduction by altering ovarian transcriptomic and metabolic signatures. J. Transl. Med. 2024;22:145. doi: 10.1186/s12967-024-04952-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Yaku K., Okabe K., Nakagawa T. NAD metabolism: Implications in aging and longevity. Ageing Res. Rev. 2018;47:1–17. doi: 10.1016/j.arr.2018.05.006. [DOI] [PubMed] [Google Scholar]
- 70.Kordowitzki P., Ho W.H.J., Listijono D.R. Nicotinamide Adenine Nucleotide-The Fountain of Youth to Prevent Oocyte Aging? Cells. 2021;10 doi: 10.3390/cells10092441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Wei S., Tang W., Chen D., Xiong J., Xue L., Dai Y., Guo Y., Wu C., Dai J., Wu M., Wang S. Multiomics insights into the female reproductive aging. Ageing Res. Rev. 2024;95 doi: 10.1016/j.arr.2024.102245. [DOI] [PubMed] [Google Scholar]
- 72.Wen C., Jiang L., Pan P., Huang J., Xie Y., Ou S., Li Y. GRSF1 deficiency attenuates mitochondrial function in aging granulosa cells. Reproduction (Cambridge, England) 2024;168 doi: 10.1530/REP-24-0015. [DOI] [PubMed] [Google Scholar]
- 73.Desai S., Wood-Trageser M., Matic J., Chipkin J., Jiang H., Bachelot A., Dulon J., Sala C., Barbieri C., Cocca M., et al. MCM8 and MCM9 Nucleotide Variants in Women With Primary Ovarian Insufficiency. J. Clin. Endocrinol. Metab. 2017;102:576–582. doi: 10.1210/jc.2016-2565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Ma L., Chen Y., Mei S., LIU C., MA X., LI Y., JIANG Y., HA L., XU X. Single nucleotide polymorphisms in premature ovarian failure-associated genes in a Chinese Hui population. Mol. Med. Rep. 2015;12:2529–2538. doi: 10.3892/mmr.2015.3762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Smits M.A.J., Schomakers B.V., van Weeghel M., Wever E.J.M., Wüst R.C.I., Dijk F., Janssens G.E., Goddijn M., Mastenbroek S., Houtkooper R.H., Hamer G. Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction. Hum. Reprod. 2023;38:2208–2220. doi: 10.1093/humrep/dead177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Zhang Z., He C., Gao Y., Zhang L., Song Y., Zhu T., Zhu K., Lv D., Wang J., Tian X., et al. α-ketoglutarate delays age-related fertility decline in mammals. Aging Cell. 2021;20 doi: 10.1111/acel.13291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Tang W., Wang K., Feng Y., Tsui K.H., Singh K.K., Stout M.B., Wang S., Wu M. Exploration of the mechanism and therapy of ovarian aging by targeting cellular senescence. Life Med. 2025;4 doi: 10.1093/lifemedi/lnaf004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Lucas V., Cavadas C., Aveleira C.A. Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies. Pharmacol. Rev. 2023;75:675–713. doi: 10.1124/pharmrev.122.000622. [DOI] [PubMed] [Google Scholar]
- 79.Xiu Z., Tang S., Kong P., Yan M., Tong X., Liu X., Liang X., Li R., Duan Y. Zigui-Yichong-Fang protects against cyclophosphamide-induced premature ovarian insufficiency via the SIRT1/Foxo3a pathway. J. Ethnopharmacol. 2023;314 doi: 10.1016/j.jep.2023.116608. [DOI] [PubMed] [Google Scholar]
- 80.Nacarelli T., Lau L., Fukumoto T., Zundell J., Fatkhutdinov N., Wu S., Aird K.M., Iwasaki O., Kossenkov A.V., Schultz D., et al. NAD(+) metabolism governs the proinflammatory senescence-associated secretome. Nat. Cell Biol. 2019;21:397–407. doi: 10.1038/s41556-019-0287-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Wang Y., Liu L., Song Y., Yu X., Deng H. Unveiling E2F4, TEAD1 and AP-1 as regulatory transcription factors of the replicative senescence program by multi-omics analysis. Protein Cell. 2022;13:742–759. doi: 10.1007/s13238-021-00894-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Martínez-Zamudio R.I., Roux P.F., de Freitas J.A.N.L.F., Robinson L., Doré G., Sun B., Belenki D., Milanovic M., Herbig U., Schmitt C.A., et al. AP-1 imprints a reversible transcriptional programme of senescent cells. Nat. Cell Biol. 2020;22:842–855. doi: 10.1038/s41556-020-0529-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Jiang X., Baig A.H., Palazzo G., Del Pizzo R., Bortecen T., Groessl S., Zaal E.A., Amaya Ramirez C.C., Kowar A., Aviles-Huerta D., et al. P53-dependent hypusination of eIF5A affects mitochondrial translation and senescence immune surveillance. Nat. Commun. 2024;15:7458. doi: 10.1038/s41467-024-51901-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.He B., Yin C., Gong Y., Liu J., Guo H., Zhao R. Melatonin-induced increase of lipid droplets accumulation and in vitro maturation in porcine oocytes is mediated by mitochondrial quiescence. J. Cell. Physiol. 2018;233:302–312. doi: 10.1002/jcp.25876. [DOI] [PubMed] [Google Scholar]
- 85.Fang Y., Zhang J., Li Y., Guo X., Li J., Zhong R., Zhang X. Melatonin-induced demethylation of antioxidant genes increases antioxidant capacity through RORα in cumulus cells of prepubertal lambs. Free Radic. Biol. Med. 2019;131:173–183. doi: 10.1016/j.freeradbiomed.2018.11.027. [DOI] [PubMed] [Google Scholar]
- 86.Di Giorgio E., Paluvai H., Dalla E., Ranzino L., Renzini A., Moresi V., Minisini M., Picco R., Brancolini C. HDAC4 degradation during senescence unleashes an epigenetic program driven by AP-1/p300 at selected enhancers and super-enhancers. Genome Biol. 2021;22:129. doi: 10.1186/s13059-021-02340-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Di Giorgio E., Dalla E., Tolotto V., D'Este F., Paluvai H., Ranzino L., Brancolini C. HDAC4 influences the DNA damage response and counteracts senescence by assembling with HDAC1/HDAC2 to control H2BK120 acetylation and homology-directed repair. Nucleic Acids Res. 2024;52:8218–8240. doi: 10.1093/nar/gkae501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Zhang Z.L., Ren S.T., Yang W.J., Xu X.W., Zhao S.M., Fang K.F., Lin Y., Yuan Y.Y., Zhang X.J., Chen Y.Q., Xu W. AARS2-catalyzed lactylation induces follicle development and premature ovarian insufficiency. Cell Death Discov. 2025;11:209. doi: 10.1038/s41420-025-02501-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Grossi E., Marchese F.P., González J., Goñi E., Fernández-Justel J.M., Amadoz A., Herranz N., Puchades-Carrasco L., Montes M., Huarte M. A lncRNA-mediated metabolic rewiring of cell senescence. Cell Rep. 2025;44 doi: 10.1016/j.celrep.2025.115747. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Li D., Wang X., Li G., Dang Y., Zhao S., Qin Y. LncRNA ZNF674-AS1 regulates granulosa cell glycolysis and proliferation by interacting with ALDOA. Cell Death Discov. 2021;7:107. doi: 10.1038/s41420-021-00493-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Jiang Y., Adhikari D., Li C., Zhou X. Spatiotemporal regulation of maternal mRNAs during vertebrate oocyte meiotic maturation. Biol. Rev. Camb. Philos. Soc. 2023;98:900–930. doi: 10.1111/brv.12937. [DOI] [PubMed] [Google Scholar]
- 92.Laranjeira A.C., Berger S., Kohlbrenner T., Greter N.R., Hajnal A. Nutritional vitamin B12 regulates RAS/MAPK-mediated cell fate decisions through one-carbon metabolism. Nat. Commun. 2024;15:8178. doi: 10.1038/s41467-024-52556-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Richani D., Gilchrist R.B. The epidermal growth factor network: role in oocyte growth, maturation and developmental competence. Hum. Reprod. Update. 2018;24:1–14. doi: 10.1093/humupd/dmx029. [DOI] [PubMed] [Google Scholar]
- 94.Han L., Huang Y., Li B., Wang W., Sun Y.L., Zhang X., Zhang W., Liu S., Zhou W., Xia W., Zhang M. The metallic compound promotes primordial follicle activation and ameliorates fertility deficits in aged mice. Theranostics. 2023;13:3131–3148. doi: 10.7150/thno.82553. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.El-Sheikh M., Mesalam A., Khalil A.A.K., Idrees M., Ahn M.J., Mesalam A.A., Kong I.K. Downregulation of PI3K/AKT/mTOR Pathway in Juglone-Treated Bovine Oocytes. Antioxidants. 2023;12 doi: 10.3390/antiox12010114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Hu L., Hong T., He Y., Wang H., Cao J., Pu D., Gao L., Gao C., Cui Y., Wu J., Tan R. Chromosome Segregation-1-like Gene Participates in Ferroptosis in Human Ovarian Granulosa Cells via Nucleocytoplasmic Transport. Antioxidants. 2024;13:911. doi: 10.3390/antiox13080911. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Castrillon D.H., Miao L., Kollipara R., Horner J.W., DePinho R.A. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (New York, N.Y.) 2003;301:215–218. doi: 10.1126/science.1086336. [DOI] [PubMed] [Google Scholar]
- 98.Covarrubias A.J., Perrone R., Grozio A., Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 2021;22:119–141. doi: 10.1038/s41580-020-00313-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Tatone C., Di Emidio G., Barbonetti A., Carta G., Luciano A.M., Falone S., Amicarelli F. Sirtuins in gamete biology and reproductive physiology: emerging roles and therapeutic potential in female and male infertility. Hum. Reprod. Update. 2018;24:267–289. doi: 10.1093/humupd/dmy003. [DOI] [PubMed] [Google Scholar]
- 100.Yang Q., Li H., Wang H., Chen W., Zeng X., Luo X., Xu J., Sun Y. Deletion of enzymes for de novo NAD(+) biosynthesis accelerated ovarian aging. Aging Cell. 2023;22 doi: 10.1111/acel.13904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Yang Q., Cong L., Wang Y., Luo X., Li H., Wang H., Zhu J., Dai S., Jin H., Yao G., et al. Increasing ovarian NAD(+) levels improve mitochondrial functions and reverse ovarian aging. Free Radic. Biol. Med. 2020;156:1–10. doi: 10.1016/j.freeradbiomed.2020.05.003. [DOI] [PubMed] [Google Scholar]
- 102.Xing X., Peng J., Zhao J., Shi R., Wang C., Zhang Z., Wang Z., Li Z., Wu Z. Luteolin regulates the distribution and function of organelles by controlling SIRT1 activity during postovulatory oocyte aging. Front. Nutr. 2023;10 doi: 10.3389/fnut.2023.1192758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Zhu J., Yang Q., Li H., Wang Y., Jiang Y., Wang H., Cong L., Xu J., Shen Z., Chen W., et al. Sirt3 deficiency accelerates ovarian senescence without affecting spermatogenesis in aging mice. Free Radic. Biol. Med. 2022;193:511–525. doi: 10.1016/j.freeradbiomed.2022.10.324. [DOI] [PubMed] [Google Scholar]
- 104.Richani D., Dunning K.R., Thompson J.G., Gilchrist R.B. Metabolic co-dependence of the oocyte and cumulus cells: essential role in determining oocyte developmental competence. Hum. Reprod. Update. 2021;27:27–47. doi: 10.1093/humupd/dmaa043. [DOI] [PubMed] [Google Scholar]
- 105.Blengini C.S., Schindler K. Follicular communication breakdown in aging ovaries. Nat. Aging. 2023;3:636–637. doi: 10.1038/s43587-023-00435-9. [DOI] [PubMed] [Google Scholar]
- 106.Voros C., Athanasiou D., Mavrogianni D., Varthaliti A., Bananis K., Athanasiou A., Athanasiou A., Papadimas G., Gkirgkinoudis A., Papapanagiotou I., et al. Exosomal Communication Between Cumulus-Oocyte Complexes and Granulosa Cells: A New Molecular Axis for Oocyte Competence in Human-Assisted Reproduction. Int. J. Mol. Sci. 2025;26 doi: 10.3390/ijms26115363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Wijayarathna R., de Kretser D.M. Activins in reproductive biology and beyond. Hum. Reprod. Update. 2016;22:342–357. doi: 10.1093/humupd/dmv058. [DOI] [PubMed] [Google Scholar]
- 108.Saraswathibhatla A., Indana D., Chaudhuri O. Cell-extracellular matrix mechanotransduction in 3D. Nat. Rev. Mol. Cell Biol. 2023;24:495–516. doi: 10.1038/s41580-023-00583-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Sun Z., Guo S.S., Fässler R. Integrin-mediated mechanotransduction. J. Cell Biol. 2016;215:445–456. doi: 10.1083/jcb.201609037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Che P., Yu L., Friedman G.K., Wang M., Ke X., Wang H., Zhang W., Nabors B., Ding Q., Han X. Integrin αvβ3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells. Cancers. 2021;13:1111. doi: 10.3390/cancers13051111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Masalmeh R.H.A., Dawson J.C., Garcia V.A., Muir M.T., Carter R.N., Hardingham G.E., Davies C., Graham R., von Kriegsheim A., Marques J., et al. FAK modulates glioblastoma stem cell energetics via regulation of glycolysis and glutamine oxidation. Dis. Model. Mech. 2025;18 doi: 10.1242/dmm.052634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Liao X., Li X., Liu R. Extracellular-matrix mechanics regulate cellular metabolism: A ninja warrior behind mechano-chemo signaling crosstalk. Rev. Endocr. Metab. Disord. 2023;24:207–220. doi: 10.1007/s11154-022-09768-z. [DOI] [PubMed] [Google Scholar]
- 113.Del Bianco D., Gentile R., Sallicandro L., Biagini A., Quellari P.T., Gliozheni E., Sabbatini P., Ragonese F., Malvasi A., D'Amato A., et al. Electro-Metabolic Coupling of Cumulus-Oocyte Complex. Int. J. Mol. Sci. 2024;25 doi: 10.3390/ijms25105349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Liu M., Zhang D., Zhou X., Duan J., Hu Y., Zhang W., Liu Q., Xu B., Zhang A. Cell-free fat extract improves ovarian function and fertility in mice with premature ovarian insufficiency. Stem Cell Res. Ther. 2022;13:320. doi: 10.1186/s13287-022-03012-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Foley K.G., Pritchard M.T., Duncan F.E. Macrophage-derived multinucleated giant cells: hallmarks of the aging ovary. Reproduction (Cambridge, England) 2021;161:V5–V9. doi: 10.1530/REP-20-0489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Jaafar C., Aguiar R.C.T. Dynamic multilayered control of m(6)A RNA demethylase activity. Proc. Natl. Acad. Sci. USA. 2024;121 doi: 10.1073/pnas.2317847121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Zhang J.N., Wang R.T., Klinger F.G., Cheng S.F., Shen W., Sun X.F. RNA m6A dynamic modification mediated by nucleus-localized FTO is involved in follicular reserve. Zool. Res. 2024;45:415–428. doi: 10.24272/j.issn.2095-8137.2023.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Zhao K., Zhang H., Yang D. SIRT1 exerts protective effects by inhibiting endoplasmic reticulum stress and NF-κB signaling pathways. Front. Cell Dev. Biol. 2024;12 doi: 10.3389/fcell.2024.1405546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Singh V., Ubaid S. Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation. Inflammation. 2020;43:1589–1598. doi: 10.1007/s10753-020-01242-9. [DOI] [PubMed] [Google Scholar]
- 120.Lu H., Jing Y., Zhang C., Ma S., Zhang W., Huang D., Zhang B., Zuo Y., Qin Y., Liu G.H., et al. Aging hallmarks of the primate ovary revealed by spatiotemporal transcriptomics. Protein Cell. 2024;15:364–384. doi: 10.1093/procel/pwad063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Tasdemir N., Banito A., Roe J.S., Alonso-Curbelo D., Camiolo M., Tschaharganeh D.F., Huang C.H., Aksoy O., Bolden J.E., Chen C.C., et al. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. Cancer Discov. 2016;6:612–629. doi: 10.1158/2159-8290.CD-16-0217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Huang F., Cao Y., Liang J., Tang R., Wu S., Zhang P., Chen R. The influence of the gut microbiome on ovarian aging. Gut Microbes. 2024;16 doi: 10.1080/19490976.2023.2295394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Zhang F., Li R., Liu Y., Liang J., Gong Y., Xiao C., Cai J., Wang T., You Q., Zhang J., et al. Integrative cross-tissue analysis unveils complement-immunoglobulin augmentation and dysbiosis-related fatty acid metabolic remodeling during mammalian aging. iMeta. 2025;4 doi: 10.1002/imt2.70027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Cheng S.Y., Yang Y.F., Wang Y.L., Yue Z.P., Chen Y.Z., Wang W.K., Xu Z.R., Li L.F., Shen H., Qi Z.M., et al. Triptolide exposure triggers ovarian inflammation by activating cGAS-STING pathway and decrease oocyte quality in mouse. Food Chem. Toxicol. 2025;196 doi: 10.1016/j.fct.2024.115201. [DOI] [PubMed] [Google Scholar]
- 125.Chu L.X., Wang W.J., Gu X.P., Wu P., Gao C., Zhang Q., Wu J., Jiang D.W., Huang J.Q., Ying X.W., et al. Spatiotemporal multi-omics: exploring molecular landscapes in aging and regenerative medicine. Mil. Med. Res. 2024;11:31. doi: 10.1186/s40779-024-00537-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Suda M., Paul K.H., Tripathi U., Minamino T., Tchkonia T., Kirkland J.L. Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction. Endocr. Rev. 2024;45:655–675. doi: 10.1210/endrev/bnae010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Zhang X., Zhang L., Xiang W. The impact of mitochondrial dysfunction on ovarian aging. J. Transl. Med. 2025;23:211. doi: 10.1186/s12967-025-06223-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Dong J., Guo C., Yang Z., Wu Y., Zhang C. Follicle-Stimulating Hormone Alleviates Ovarian Aging by Modulating Mitophagy- and Glycophagy-Based Energy Metabolism in Hens. Cells. 2022;11 doi: 10.3390/cells11203270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Zhang Y.R., Xu D.J. Mitochondrial Quality Control in Bovine Oocyte Maturation: Mechanisms, Challenges, and Prospects for Enhancing Reproductive Efficiency. Animals. 2025;15 doi: 10.3390/ani15132000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Yildirim R.M., Seli E. The role of mitochondrial dynamics in oocyte and early embryo development. Semin. Cell Dev. Biol. 2024;159–160:52–61. doi: 10.1016/j.semcdb.2024.01.007. [DOI] [PubMed] [Google Scholar]
- 131.Zhou Y., Jin Y., Wu T., Wang Y., Dong Y., Chen P., Hu C., Pan N., Ye C., Shen L., et al. New insights on mitochondrial heteroplasmy observed in ovarian diseases. J. Adv. Res. 2024;65:211–226. doi: 10.1016/j.jare.2023.11.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Cohen J., Scott R., Schimmel T., Levron J., Willadsen S. Birth of infant after transfer of anucleate donor oocyte cytoplasm into recipient eggs. Lancet (London, England) 1997;350:186–187. doi: 10.1016/S0140-6736(05)62353-7. [DOI] [PubMed] [Google Scholar]
- 133.Costa-Borges N., Nikitos E., Späth K., Miguel-Escalada I., Ma H., Rink K., Coudereau C., Darby H., Koski A., Van Dyken C., et al. First pilot study of maternal spindle transfer for the treatment of repeated in vitro fertilization failures in couples with idiopathic infertility. Fertil. Steril. 2023;119:964–973. doi: 10.1016/j.fertnstert.2023.02.008. [DOI] [PubMed] [Google Scholar]
- 134.Chen S.H., Pascale C., Jackson M., Szvetecz M.A., Cohen J. A limited survey-based uncontrolled follow-up study of children born after ooplasmic transplantation in a single centre. Reprod. Biomed. Online. 2016;33:737–744. doi: 10.1016/j.rbmo.2016.10.003. [DOI] [PubMed] [Google Scholar]
- 135.Chiang J.L., Shukla P., Pagidas K., Ahmed N.S., Karri S., Gunn D.D., Hurd W.W., Singh K.K. Mitochondria in Ovarian Aging and Reproductive Longevity. Ageing Res. Rev. 2020;63 doi: 10.1016/j.arr.2020.101168. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Luce J. Mitochondrial replacement techniques: The perspectives of mitochondrial disease specialists in Germany. Soc. Sci. Med. 1982;382 doi: 10.1016/j.socscimed.2025.118177. [DOI] [PubMed] [Google Scholar]
- 137.Zhang X., Zhang W., Wang Z., Zheng N., Yuan F., Li B., Li X., Deng L., Lin M., Chen X., Zhang M. Enhanced glycolysis in granulosa cells promotes the activation of primordial follicles through mTOR signaling. Cell Death Dis. 2022;13:87. doi: 10.1038/s41419-022-04541-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Wang N., Luo L.L., Xu J.J., Xu M.Y., Zhang X.M., Zhou X.L., Liu W.J., Fu Y.C. Obesity accelerates ovarian follicle development and follicle loss in rats. Metabolism. 2014;63:94–103. doi: 10.1016/j.metabol.2013.09.001. [DOI] [PubMed] [Google Scholar]
- 139.Calubag M.F., Robbins P.D., Lamming D.W. A nutrigeroscience approach: Dietary macronutrients and cellular senescence. Cell Metab. 2024;36:1914–1944. doi: 10.1016/j.cmet.2024.07.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Di Emidio G., Vergara T., Konstantinidou F., Flati I., Stuppia L., Artini P.G., Gatta V., Falone S., Tatone C. NAD(+) Metabolism and Mitochondrial Activity in the Aged Oocyte: Focus on the Effects of NAMPT Stimulation. Aging Dis. 2024;15:2828–2851. doi: 10.14336/AD.2024.0241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Xie N., Zhang L., Gao W., Huang C., Huber P.E., Zhou X., Li C., Shen G., Zou B. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 2020;5:227. doi: 10.1038/s41392-020-00311-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Wu M., Guo Y., Wei S., Xue L., Tang W., Chen D., Xiong J., Huang Y., Fu F., Wu C., et al. Biomaterials and advanced technologies for the evaluation and treatment of ovarian aging. J. Nanobiotechnol. 2022;20:374. doi: 10.1186/s12951-022-01566-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Ye R., Mao Y.M., Fei Y.R., Shang Y., Zhang T., Zhang Z.Z., Liu Y.L., Li J.Y., Chen S.L., He Y.B. Targeting ferroptosis for the treatment of female reproductive system disorders. J. Mol. Med. 2025;103:381–402. doi: 10.1007/s00109-025-02528-x. [DOI] [PubMed] [Google Scholar]
- 144.Xu B., Deng Y., Dai W., Shang Y., Ding L., Zhang Z., Yang H., He T., Pei X., Fu X. 3D cultured human umbilical cord mesenchymal stem cell spheroids regulate oxidative stress and iron homeostasis through the Nrf2 pathway to resist ferroptosis in ovarian granulosa cells and ovarian dysfunction. Free Radic. Biol. Med. 2025;236:28–40. doi: 10.1016/j.freeradbiomed.2025.05.396. [DOI] [PubMed] [Google Scholar]
- 145.Dang L., Dong Y., Zhang C., Su B., Ning N., Zhou S., Zhang M., Huang Q., Li Y., Wang S. Zishen Yutai pills restore fertility in premature ovarian failure through regulating arachidonic acid metabolism and the ATK pathway. J. Ethnopharmacol. 2024;324 doi: 10.1016/j.jep.2024.117782. [DOI] [PubMed] [Google Scholar]
- 146.Dandan W., Shanshan L., Ranpei Z., Zongqing H., Fan Q., Wenwen Q., Xiaopeng L., Yujie L., Yurun W., Qingbo W. Acupuncture modulates ovarian senescence through metabolic reprogramming: A multi-omics investigation in chemotherapy - induced POF model. Exp. Gerontol. 2025;209 doi: 10.1016/j.exger.2025.112815. [DOI] [PubMed] [Google Scholar]
- 147.Jung D., Xiong J., Ye M., Qin X., Li L., Cheng S., Luo M., Peng J., Dong J., Tang F., et al. In vitro differentiation of human embryonic stem cells into ovarian follicle-like cells. Nat. Commun. 2017;8 doi: 10.1038/ncomms15680. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Li J., Fan H., Liu W., Zhang J., Xiao Y., Peng Y., Yang W., Liu W., He Y., Qin L., et al. Mesenchymal stem cells promote ovarian reconstruction in mice. Stem Cell Res. Ther. 2024;15:115. doi: 10.1186/s13287-024-03718-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Zhou Y., Huang J., Zeng L., Yang Q., Bai F., Mai Q., Deng K. Human mesenchymal stem cells derived exosomes improve ovarian function in chemotherapy-induced premature ovarian insufficiency mice by inhibiting ferroptosis through Nrf2/GPX4 pathway. J. Ovarian Res. 2024;17:80. doi: 10.1186/s13048-024-01403-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 150.Cao J., Huo P., Cui K., Wei H., Cao J., Wang J., Liu Q., Lei X., Zhang S. Follicular fluid-derived exosomal miR-143-3p/miR-155-5p regulate follicular dysplasia by modulating glycolysis in granulosa cells in polycystic ovary syndrome. Cell Commun. Signal. 2022;20:61. doi: 10.1186/s12964-022-00876-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Ding C., Qian C., Hou S., Lu J., Zou Q., Li H., Huang B. Exosomal miRNA-320a Is Released from hAMSCs and Regulates SIRT4 to Prevent Reactive Oxygen Species Generation in POI, Molecular therapy. Nucleic Acids. 2020;21:37–50. doi: 10.1016/j.omtn.2020.05.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152.Francés-Herrero E., Lopez R., Hellström M., de Miguel-Gómez L., Herraiz S., Brännström M., Pellicer A., Cervelló I. Bioengineering trends in female reproduction: a systematic review. Hum. Reprod. Update. 2022;28:798–837. doi: 10.1093/humupd/dmac025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Li W., Lu M., Shang J., Zhou J., Lin L., Liu Y., Zhao D., Zhu X. Hypoxic mesenchymal stem cell-derived exosomal circDennd2a regulates granulosa cell glycolysis by interacting with LDHA. Stem Cell Res. Ther. 2024;15:484. doi: 10.1186/s13287-024-04098-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154.Zhang S., Zhu D., Li Z., Huang K., Hu S., Lutz H., Xie M., Mei X., Li J., Neal-Perry G., et al. A stem cell-derived ovarian regenerative patch restores ovarian function and rescues fertility in rats with primary ovarian insufficiency. Theranostics. 2021;11:8894–8908. doi: 10.7150/thno.61690. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155.Liu M., Zhu H., Zhou X., Duan J., Shen Y., Zhang A. Cell-free fat extract prevents diminished ovarian reserve by inhibiting granulosa cell senescence. Stem Cell Res. Ther. 2025;16:269. doi: 10.1186/s13287-025-04383-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156.Ren R., Ocampo A., Liu G.H., Izpisua Belmonte J.C. Regulation of Stem Cell Aging by Metabolism and Epigenetics. Cell Metab. 2017;26:460–474. doi: 10.1016/j.cmet.2017.07.019. [DOI] [PubMed] [Google Scholar]
- 157.Secomandi L., Borghesan M., Velarde M., Demaria M. The role of cellular senescence in female reproductive aging and the potential for senotherapeutic interventions. Hum. Reprod. Update. 2022;28:172–189. doi: 10.1093/humupd/dmab038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.Palmer A.K., Tchkonia T., Kirkland J.L. Targeting cellular senescence in metabolic disease. Mol. Metab. 2022;66 doi: 10.1016/j.molmet.2022.101601. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159.Chaib S., Tchkonia T., Kirkland J.L. Cellular senescence and senolytics: the path to the clinic. Nat. Med. 2022;28:1556–1568. doi: 10.1038/s41591-022-01923-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160.Zhang H., Xu Q., Jiang Z., Sun R., Wang Q., Liu S., Luan X., Campisi J., Kirkland J.L., Zhang W., Sun Y. Targeting Senescence with Apigenin Improves Chemotherapeutic Efficacy and Ameliorates Age-Related Conditions in Mice. Adv. Sci. 2025;12 doi: 10.1002/advs.202412950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 161.Zumerle S., Alimonti A. In and out from senescence. Nat. Cell Biol. 2020;22:753–754. doi: 10.1038/s41556-020-0540-x. [DOI] [PubMed] [Google Scholar]
- 162.Winstanley Y.E., Stables J.S., Gonzalez M.B., Umehara T., Norman R.J., Robker R.L. Emerging therapeutic strategies to mitigate female and male reproductive aging. Nat. Aging. 2024;4:1682–1696. doi: 10.1038/s43587-024-00771-4. [DOI] [PubMed] [Google Scholar]
- 163.Ji S., Xiong M., Chen H., Liu Y., Zhou L., Hong Y., Wang M., Wang C., Fu X., Sun X. Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases. Signal Transduct. Target. Ther. 2023;8:116. doi: 10.1038/s41392-023-01343-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 164.Hahn O., Grönke S., Stubbs T.M., Ficz G., Hendrich O., Krueger F., Andrews S., Zhang Q., Wakelam M.J., Beyer A., et al. Dietary restriction protects from age-associated DNA methylation and induces epigenetic reprogramming of lipid metabolism. Genome Biol. 2017;18:56. doi: 10.1186/s13059-017-1187-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 165.Huang X.C., Jiang Y.N., Bao H.J., Wang J.L., Lin R.J., Yuan J., Xian J.Y., Zhao Y., Chen S. Role and Mechanism of Epigenetic Regulation in the Aging of Germ Cells: Prospects for Targeted Interventions. Aging Disease. 2024;16:146–167. doi: 10.14336/AD.2024.0126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 166.Pereira B., Correia F.P., Alves I.A., Costa M., Gameiro M., Martins A.P., Saraiva J.A. Epigenetic reprogramming as a key to reverse ageing and increase longevity. Ageing Res. Rev. 2024;95 doi: 10.1016/j.arr.2024.102204. [DOI] [PubMed] [Google Scholar]
- 167.Wang K., Liu H., Hu Q., Wang L., Liu J., Zheng Z., Zhang W., Ren J., Zhu F., Liu G.H. Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct. Target. Ther. 2022;7:374. doi: 10.1038/s41392-022-01211-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 168.Zhang X., Cao Q., Rajachandran S., Grow E.J., Evans M., Chen H. Dissecting mammalian reproduction with spatial transcriptomics. Hum. Reprod. Update. 2023;29:794–810. doi: 10.1093/humupd/dmad017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 169.Chen Y., Yang S., Yu K., Zhang J., Wu M., Zheng Y., Zhu Y., Dai J., Wang C., Zhu X., et al. Spatial omics: An innovative frontier in aging research. Ageing Res. Rev. 2024;93 doi: 10.1016/j.arr.2023.102158. [DOI] [PubMed] [Google Scholar]
- 170.Wang S., Zheng Y., Li J., Yu Y., Zhang W., Song M., Liu Z., Min Z., Hu H., Jing Y., et al. Single-Cell Transcriptomic Atlas of Primate Ovarian Aging. Cell. 2020;180:585–600.e19. doi: 10.1016/j.cell.2020.01.009. [DOI] [PubMed] [Google Scholar]
- 171.Zhang Y., Yan Z., Qin Q., Nisenblat V., Chang H.M., Yu Y., Wang T., Lu C., Yang M., Yang S., et al. Transcriptome Landscape of Human Folliculogenesis Reveals Oocyte and Granulosa Cell Interactions. Mol. Cell. 2018;72:1021–1034.e4. doi: 10.1016/j.molcel.2018.10.029. [DOI] [PubMed] [Google Scholar]
- 172.Wang J.J., Tian Y., Li M.H., Feng Y.Q., Kong L., Zhang F.L., Shen W. Single-cell transcriptome dissection of the toxic impact of Di (2-ethylhexyl) phthalate on primordial follicle assembly. Theranostics. 2021;11:4992–5009. doi: 10.7150/thno.55006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 173.Kronja I., Whitfield Z.J., Yuan B., Dzeyk K., Kirkpatrick J., Krijgsveld J., Orr-Weaver T.L. Quantitative proteomics reveals the dynamics of protein changes during Drosophila oocyte maturation and the oocyte-to-embryo transition. Proc. Natl. Acad. Sci. USA. 2014;111:16023–16028. doi: 10.1073/pnas.1418657111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 174.Hu W., Zeng H., Shi Y., Zhou C., Huang J., Jia L., Xu S., Feng X., Zeng Y., Xiong T., et al. Single-cell transcriptome and translatome dual-omics reveals potential mechanisms of human oocyte maturation. Nat. Commun. 2022;13:5114. doi: 10.1038/s41467-022-32791-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 175.Deryabin P.I., Borodkina A.V. Epigenetic clocks provide clues to the mystery of uterine ageing. Hum. Reprod. Update. 2023;29:259–271. doi: 10.1093/humupd/dmac042. [DOI] [PubMed] [Google Scholar]




